Ignyta 10-Q 12 Aug 14 2014 Q2 Quarterly report Financial data

Document_and_Entity_Informatio

Document and Entity Information	6 Months Ended
	Jun. 30, 2014	Aug. 01, 2014
Document And Entity Information [Abstract]	'	'
Document Type	'10-Q	'
Amendment Flag	'false	'
Document Period End Date	30-Jun-14	'
Document Fiscal Year Focus	'2014	'
Document Fiscal Period Focus	'Q2	'
Trading Symbol	'RXDX	'
Entity Registrant Name	'IGNYTA, INC.	'
Entity Central Index Key	'0001557421	'
Current Fiscal Year End Date	'--12-31	'
Entity Filer Category	'Smaller Reporting Company	'
Entity Common Stock, Shares Outstanding	'	19,579,588

Condensed_Balance_Sheets

Condensed Balance Sheets (USD $)	Jun. 30, 2014	Dec. 31, 2013
Current Assets	'	'
Cash and cash equivalents	$34,564,871	$51,803,716
Short term investments	40,839,020	'
Prepaid expenses and other current assets	848,285	671,373
Total current assets	76,252,176	52,475,089
Fixed Assets - Net	2,529,229	830,706
Long term investments	19,742,553	'
Other Assets	63,045	13,045
Assets, Total	98,587,003	53,318,840
Current Liabilities	'	'
Accounts payable	1,987,766	811,600
Accrued expenses and other liabilities	1,602,916	590,235
Note payable, current portion	1,525,442	'
Warrant liability	181,800	129,400
Total current liabilities	5,297,924	1,531,235
Note payable, net of current portion and discount	7,572,021	8,950,000
Other liabilities	1,050,000	1,050,000
Total liabilities	13,919,945	11,531,235
Commitments and Contingencies (Note 11)	'	'
Stockholders' Equity	'	'
Preferred Stock, $.0001 par value; 10,000,000 shares authorized; no shares issued or outstanding	0	0
Common Stock, $.0001 par value; 150,000,000 shares authorized 19,579,588 and 13,934,876 shares issued and outstanding, respectively	1,958	1,393
Additional paid-in capital	109,761,792	57,359,152
Deficit accumulated during the development stage	-25,102,254	-15,572,940
Accumulated other comprehensive income	5,562	'
Total stockholders' equity	84,667,058	41,787,605
Liabilities and Equity, Total	$98,587,003	$53,318,840

Condensed_Balance_Sheets_Paren

Condensed Balance Sheets (Parenthetical) (USD $)	Jun. 30, 2014	Dec. 31, 2013
Statement Of Financial Position [Abstract]	'	'
Preferred Stock, par value	$0.00	$0.00
Preferred Stock, shares authorized	10,000,000	10,000,000
Preferred Stock, shares issued	0	0
Preferred Stock, shares outstanding	0	0
Common Stock, par value	$0.00	$0.00
Common Stock, shares authorized	150,000,000	150,000,000
Common Stock, shares issued	19,579,588	13,934,876
Common Stock, shares outstanding	19,579,588	13,934,876

Unaudited_Condensed_Statements

Unaudited Condensed Statements of Operations and Comprehensive Loss (USD $)	3 Months Ended		6 Months Ended		34 Months Ended
	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014
Income Statement [Abstract]	'	'	'	'	'
Revenue	$150,000	'	$150,000	'	$150,000
Expenses	'	'	'	'	'
Research and development	3,575,787	584,920	5,758,367	1,220,664	16,677,146
General and administrative	2,038,721	527,365	3,794,965	903,696	8,113,362
Loss from Operations	-5,464,508	-1,112,285	-9,403,332	-2,124,360	-24,640,508
Other Income (Expense)	'	'	'	'	'
Other income (expense)	-25,637	-7,100	-52,658	5,700	-158,610
Interest income (expense)	67,622	-22,017	-68,020	-35,475	-294,428
Total Other Income (Expense)	41,985	-29,117	-120,678	-29,775	-453,038
Loss Before Income Taxes	-5,422,523	-1,141,402	-9,524,010	-2,154,135	-25,093,546
Income tax provision	'	'	5,304	2,095	8,708
Net Loss	-5,422,523	-1,141,402	-9,529,314	-2,156,230	-25,102,254
Basic and diluted loss per share	($0.28)	($0.84)	($0.56)	($2.13)	'
Weighted average shares	19,578,733	1,366,705	17,054,031	1,011,990	'
Comprehensive Loss	'	'	'	'	'
Net loss	-5,422,523	-1,141,402	-9,529,314	-2,156,230	-25,102,254
Unrealized gain on available for sale securities	36,678	'	5,562	'	5,562
Comprehensive loss	($5,385,845)	($1,141,402)	($9,523,752)	($2,156,230)	($25,096,692)

Condensed_Statements_of_Stockh

Condensed Statements of Stockholders' Equity (USD $)

Total

Series A Preferred Stock [Member]

Series B Preferred Stock [Member]

Convertible Preferred Stock Series A [Member]

Convertible Preferred Stock Series A [Member]

Convertible Preferred Stock Series B [Member]

Convertible Preferred Stock Series B [Member]

Common Stock [Member]

Additional Paid-in Capital [Member]

Additional Paid-in Capital [Member]

Additional Paid-in Capital [Member]

Accumulated Deficit during Development Stage [Member]

Accumulated Other Comprehensive Income (Loss) [Member]

Series A Preferred Stock [Member]

Series B Preferred Stock [Member]

Series A Preferred Stock [Member]

Series B Preferred Stock [Member]

Balance at Aug. 28, 2011

$0

'

'

$0

'

$0

'

$0

$0

'

'

$0

$0

Balance (in shares) at Aug. 28, 2011

'

'

'

0

'

0

'

0

'

'

'

'

'

Issuance of Restricted Stock

2,000

'

'

'

'

'

'

66

1,934

'

'

'

'

Issuance of Restricted Stock (in shares)

'

'

'

'

'

'

'

666,668

'

'

'

'

'

Issuance of Stock net in offering costs

'

220,778

'

'

42

'

'

'

'

220,736

'

'

'

Issuance of Stock net in offering costs (in shares)

'

'

'

'

416,667

'

'

'

'

'

'

'

'

Stock-based compensation expense

781

'

'

'

'

'

'

'

781

'

'

'

'

Net loss

-79,445

'

'

'

'

'

'

'

'

'

'

-79,445

'

Balance at Dec. 31, 2011

144,114

'

'

42

'

0

'

66

223,451

'

'

-79,445

'

Balance (in shares) at Dec. 31, 2011

'

'

'

416,667

'

0

'

666,668

'

'

'

'

'

Repurchase of Common Stock

-40

'

'

'

'

'

'

-1

-39

'

'

'

'

Repurchase of Common Stock (in shares)

-13,334

'

'

0

'

'

'

-13,334

'

'

'

'

'

Issuance of Stock net in offering costs

'

249,142

5,424,031

'

42

'

183

'

'

249,100

5,423,848

'

'

Issuance of Stock net in offering costs (in shares)

'

'

'

'

416,667

'

1,835,000

'

'

'

'

'

'

Stock-based compensation expense

23,373

'

'

'

'

'

'

'

23,373

'

'

'

'

Net loss

-1,279,852

'

'

'

'

'

'

'

'

'

'

-1,279,852

'

Balance at Dec. 31, 2012

4,560,768

'

'

84

'

183

'

65

5,919,733

'

'

-1,359,297

'

Balance (in shares) at Dec. 31, 2012

'

'

'

833,334

'

1,835,000

'

653,334

'

'

'

'

'

Issuance of Common Stock due to stock options exercised

3,000

'

'

'

'

'

'

1

2,999

'

'

'

'

Issuance of Common Stock due to stock options exercised (in shares)

12,290

'

'

'

'

'

'

12,290

'

'

'

'

'

Issuance of Restricted Stock due to Actagene merger

5,700

'

'

'

'

'

'

158

5,542

'

'

'

'

Issuance of Restricted Stock due to Actagene merger (in shares)

'

'

'

'

'

'

'

1,583,336

'

'

'

'

'

Conversion of Common Stock due to reverse merger

'

'

'

-84

'

-183

'

267

'

'

'

'

'

Conversion of Common Stock due to reverse merger (in share)

'

'

'

-833,334

'

-1,835,000

'

2,675,678

'

'

'

'

'

Issuance of Stock net in offering costs

51,013,741

'

'

'

'

'

'

902

51,012,839

'

'

'

'

Issuance of Stock net in offering costs (in shares)

'

'

'

'

'

'

'

9,010,238

'

'

'

'

'

Stock-based compensation expense

370,439

'

'

'

'

'

'

'

370,439

'

'

'

'

Issuance of Warrant

47,600

'

'

'

'

'

'

'

47,600

'

'

'

'

Net loss

-14,213,643

'

'

'

'

'

'

'

'

'

'

-14,213,643

'

Balance at Dec. 31, 2013

41,787,605

'

'

0

'

0

'

1,393

57,359,152

'

'

-15,572,940

'

Balance (in shares) at Dec. 31, 2013

'

'

'

0

'

0

'

13,934,876

'

'

'

'

'

Issuance of Common Stock due to stock options exercised

5,472

'

'

'

'

'

'

2

5,470

'

'

'

'

Issuance of Common Stock due to stock options exercised (in shares)

12,962

'

'

'

'

'

'

12,962

'

'

'

'

'

Repurchase of Restricted Stock

-1,440

'

'

'

'

'

'

-40

-1,400

'

'

'

'

Repurchase of Restricted Stock (in shares)

'

'

'

'

'

'

'

-400,000

'

'

'

'

'

Issuance of Stock net in offering costs

51,581,843

'

'

'

'

'

'

603

51,581,240

'

'

'

'

Issuance of Stock net in offering costs (in shares)

'

'

'

'

'

'

'

6,031,750

'

'

'

'

'

Stock-based compensation expense

817,330

'

'

'

'

'

'

'

817,330

'

'

'

'

Unrealized gain on available for sale securities

5,562

'

'

'

'

'

'

'

'

'

'

'

5,562

Net loss

-9,529,314

'

'

'

'

'

'

'

'

'

'

-9,529,314

'

Balance at Jun. 30, 2014

$84,667,058

'

'

$0

'

$0

'

$1,958

$109,761,792

'

'

($25,102,254)

$5,562

Balance (in shares) at Jun. 30, 2014

'

'

'

0

'

0

'

19,579,588

'

'

'

'

'

Condensed_Statements_of_Stockh1

Condensed Statements of Stockholders' Equity (Parenthetical) (USD $)	6 Months Ended	12 Months Ended	4 Months Ended	12 Months Ended
	Jun. 30, 2014	Dec. 31, 2013	Dec. 31, 2011	Dec. 31, 2012	Dec. 31, 2012
	Common Stock [Member]	Common Stock [Member]	Series A Preferred Stock [Member]	Series A Preferred Stock [Member]	Series B Preferred Stock [Member]
			Convertible Preferred Stock Series A [Member]	Convertible Preferred Stock Series A [Member]	Convertible Preferred Stock Series B [Member]
Issuance of Stock, offering costs	$3,608,670	$3,047,687	$29,221	$858	$80,969

Unaudited_Condensed_Statements1

Unaudited Condensed Statements of Cash Flows (USD $)	6 Months Ended		34 Months Ended
	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014
Cash Flows From Operating Activities	'	'	'
Net loss	($9,529,314)	($2,156,230)	($25,102,254)
Adjustments to reconcile net loss to net cash used in operating activities:	'	'	'
Depreciation	111,708	48,076	237,980
Loss on sale of assets	1,437	'	30,788
Stock-based compensation	817,330	42,226	1,211,923
Non-cash interest expense	'	12,700	110,756
Change in fair value of warrant liabilities	52,400	-5,700	129,000
Accretion and amortization on debt securities	285,540	'	285,540
Warrant issued for license agreement	'	'	47,600
Amortization of debt discount	147,463	5,494	200,263
Increase (decrease) in cash resulting from changes in:	'	'	'
Prepaid expenses and other current assets	-226,912	-102,349	-1,022,086
Accounts payable trade	1,176,166	25,098	1,987,766
Accrued expenses and other liabilities	912,681	74,694	1,502,916
Net cash used in operating activities	-6,251,501	-2,055,991	-20,379,808
Cash Flows From Investing Activities	'	'	'
Purchases of investments	-62,332,770	'	-62,332,770
Sales of investments	1,471,219	'	1,471,219
Purchases of fixed assets	-1,711,668	-246,585	-2,707,997
Proceeds received from sale of assets	'	'	10,000
Net cash used by investing activities	-62,573,219	-246,585	-63,559,548
Cash Flows From Financing Activities	'	'	'
Net proceeds from issuance of Common Stock	51,581,843	'	102,595,584
Proceeds from issuance of notes payable	'	500,000	11,500,000
Payments on notes payable	'	'	-1,500,000
Net proceeds from issuance of Restricted Stock	'	5,700	7,700
Net proceeds from issuance of Preferred Stock	'	'	5,893,951
Net proceeds from stock options exercised	5,472	'	8,472
Repurchase of Common Stock	-1,440	'	-1,480
Net cash provided by financing activities	51,585,875	505,700	118,504,227
Net Change in Cash and Cash Equivalents	-17,238,845	-1,796,876	34,564,871
Cash and Cash Equivalents at Beginning of Period	51,803,716	5,032,307	'
Cash and Cash Equivalents at End of Period	34,564,871	3,235,431	34,564,871
Supplemental Disclosures of Cash Flow Information:	'	'	'
Interest	292,178	17,282	353,634
Income taxes	5,304	2,095	8,708
Noncash investing and Financing Activities:	'	'	'
Warrants issued with debt financing recorded as debt discount	'	12,100	52,800
Leasehold improvement paid by landlord	100,000	'	100,000
Unrealized gain on available for sale securities	$5,562	'	$5,562

Summary_of_Significant_Account

Summary of Significant Accounting Policies	6 Months Ended
	Jun. 30, 2014
Accounting Policies [Abstract]	'
Summary of Significant Accounting Policies	'
	1.      Summary of Significant Accounting Policies	A summary of the Company’s significant accounting policies consistently applied in the preparation of the accompanying financial statements follows.
	Nature of operations	Ignyta, Inc. (“Ignyta”) was founded in 2011 and is incorporated in the state of Delaware. On June 12, 2014, Ignyta, Inc. merged with and into Ignyta Operating, Inc. with Ignyta Operating, Inc. surviving the merger and changing its name to Ignyta, Inc.
		On October 31, 2013, Ignyta merged with and into IGAS Acquisition Corp., a wholly-owned subsidiary of Ignyta, Inc., a Nevada corporation previously named Infinity Oil & Gas Company (see Note 2). As used in these financial statements, unless the context indicates or otherwise requires, the “Company”, “we”, “us”, and “our” refer to Ignyta.
		In May 2013, the Company acquired Actagene Oncology, Inc. (“Actagene”), a San Diego based privately held biotechnology company developing precision medicines for high unmet need cancer indications, based on cancer genome mining and sequencing. With the acquisition, the Company changed its business strategy from a prior focus on molecular diagnostics for autoimmune disease to an integrated drug and diagnostic, or Rx/Dx, focus on drug and biomarker discovery and development for oncology (see Note 3).
		The Company is a precision medicine biotechnology company dedicated to discovering or acquiring, then developing and commercializing, precisely targeted new drugs for cancer patients whose tumors harbor specific molecular alterations. The Company pursues an Rx/Dx strategy, where it aims to pair each of its innovative drugs with biomarker-based companion diagnostics, developed by the Company or by third parties with which it may partner, that are designed to identify the patients that are most likely to benefit from the use of the drugs that the Company may develop.
	Basis of Presentation	The accompanying unaudited condensed financial statements have been prepared in accordance with U.S. generally accepted accounting principles (“GAAP”) for interim financial information, the instructions to Form 10-Q and related Securities and Exchange Commission (“SEC”) rules and regulations. Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. In management’s opinion, the accompanying financial statements reflect all adjustments, consisting of normal recurring adjustments, considered necessary for a fair presentation of the results for the interim periods presented.
		Interim financial results are not necessarily indicative of results anticipated for the full year. These unaudited financial statements should be read in conjunction with the Company’s audited financial statements and footnotes included in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2013, from which the balance sheet information herein was derived.
		The preparation of financial statements requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenue and expenses, and related disclosure of contingent assets and liabilities. Actual results could differ from those estimates.
	Development stage	As of June 30, 2014, the Company has devoted substantially all of its efforts to product development, raising capital and building infrastructure, and has not realized revenues from its planned principal operations. Accordingly, the Company is considered to be in the development stage.
	Liquidity	As of June 30, 2014, the Company had an accumulated deficit of approximately $25,102,000. The Company also had negative cash flow from operations of approximately $6,252,000 during the six months ended June 30, 2014.
		The Company expects that it will need additional capital to further fund development of, and seek regulatory approvals for, its product candidates, and begin to commercialize any approved products.
		We are currently focused primarily on the development of our RXDX-101, Spark-1, Spark-2 and Spark-3 programs, and we intend to devote resources to our newly-licensed RXDX-103 and RXDX-104 programs. We believe such activities will result in our continued incurrence of significant research and development and other expenses related to those programs. If the clinical trials for any of our products fail or produce unsuccessful results and those product candidates do not gain regulatory approval, or if any of our product candidates, if approved, fails to achieve market acceptance, we may never become profitable. Even if we achieve profitability in the future, we may not be able to sustain profitability in subsequent periods. The Company intends to cover its future operating expenses through cash on hand and through additional financing from existing and prospective investors. We cannot be sure that additional financing will be available when needed or that, if available, financing will be obtained on terms favorable to us or to our stockholders.
		While we expect that our existing cash and cash equivalents will enable us to fund our operations and capital expenditure requirements for at least the next twelve months, having insufficient funds may require us to delay, reduce, or eliminate some or all of our development programs. Failure to obtain adequate financing could eventually adversely affect our ability to operate as a going concern. If we raise additional funds from the issuance of equity securities, substantial dilution to our existing stockholders would likely result. If we raise additional funds by incurring debt financing, the terms of the debt may involve significant cash payment obligations as well as covenants and specific financial ratios that may restrict our ability to operate our business.
	Use of estimates	The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenue and expenses, and related disclosure of contingent assets and liabilities. Actual results could differ from those estimates. Significant estimates used in preparing the financial statements include those assumed in computing the valuation allowance on deferred tax assets and the valuation of warrants, and those assumed in calculating stock-based compensation expense.
	Cash and cash equivalents	The Company considers all highly liquid investments with an original maturity of 90 days or less when purchased to be cash equivalents. Cash equivalents primarily represent amounts invested in money market funds whose cost equals market value.
	Investments	Investments consist of corporate notes and bonds and commercial paper. The Company classifies investments as available-for-sale at the time of purchase. All investments are recorded at estimated fair value. Unrealized gains and losses for available-for-sale securities are included in accumulated other comprehensive income, a component of stockholders’ equity. The Company evaluates its investments as of each balance sheet date to assess whether those with unrealized loss positions are other-than-temporarily impaired. Impairments are considered to be other-than-temporary if they are related to deterioration in credit risk or if it is likely that the Company will sell the securities before the recovery of its cost basis. Realized gains and losses and declines in value judged to be other-than-temporary are determined based on the specific identification method and are reported in other income (expense), net in the Statements of Operations. No other-than-temporary impairment charges have been recognized since inception.
	Fixed assets	Fixed assets are recorded at cost. Depreciation is computed using the straight-line method over the estimated useful lives of the related assets, generally three to seven years, or, in the case of leasehold improvements, over the lesser of the useful life of the related asset or the lease term.
	Impairment of long-lived assets	In accordance with authoritative guidance related to impairment or disposal of long-lived assets, management reviews the Company’s long-lived asset groups for impairment whenever events indicate that their book value may not be recoverable. When management determines that one or more impairment indicators are present for an asset group, it compares the book value of the asset group to net future undiscounted cash flows that the asset group is expected to generate. If the book value of the asset group is greater than the net future undiscounted cash flows that the asset group is expected to generate, it compares the fair value to the book value of the asset group. If the fair value is less than the book value, it recognizes an impairment loss. The impairment loss would be the excess of the book value of the asset group over its fair value. To date, the Company has not experienced any impairment losses on its long-lived assets used in operations.
	Stock-based compensation	The Company accounts for stock-based compensation in accordance with Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) Topic 718, Compensation—Stock Compensation, which establishes accounting for equity instruments exchanged for employee services. Under such provisions, stock-based compensation cost is measured at the grant date, based on the calculated fair value of the award, and is recognized as an expense, under the straight-line method, over the employee’s requisite service period (generally the vesting period of the equity grant).
		The Company accounts for equity instruments, including restricted stock or stock options, issued to non-employees in accordance with authoritative guidance for equity based payments to non-employees. Stock options issued to non-employees are accounted for at their estimated fair value determined using the Black-Scholes option-pricing model. The fair value of options granted to non-employees is re-measured as they vest, and the resulting increase in value, if any, is recognized as expense during the period the related services are rendered. Restricted stock issued to non-employees is accounted for at its estimated fair value as it vests.
	Fair value of financial instruments	The Company’s financial instruments consist of cash and cash equivalents, investments, prepaid expenses and other assets, accounts payable, accrued expenses, and notes payable. Fair value estimates of these instruments at a specific point in time are made based on relevant market information. These estimates may be subjective in nature and involve uncertainties and matters of significant judgment and therefore cannot be determined with precision. As of June 30, 2014 and December 31, 2013, the book values are generally considered to be representative of their respective fair values because of the short-term nature of those instruments.
	Derivative liabilities	The Company accounts for its warrants as either equity or liabilities based upon the characteristics and provisions of each instrument. Warrants classified as derivative liabilities are recorded on the Company’s balance sheet at their fair value on the date of issuance and revalued on each subsequent balance sheet date until such instruments are exercised or expire, with any changes in the fair value between reporting periods recorded as other income or expense. Management estimates the fair value of these liabilities using option pricing models and assumptions that are based on the individual characteristics of the warrants or instruments on the valuation date, as well as assumptions for future events, expected volatility, expected life, yield, and risk free interest rate.
	Income taxes	Deferred income taxes are recognized for the tax consequences in future years of differences between the tax basis of assets and liabilities and their financial reporting amounts at each year end based on enacted tax laws and statutory tax rates applicable to the periods in which the differences are expected to affect taxable income. Valuation allowances are established when necessary to reduce deferred tax assets to the amount expected to be realized. Income tax expense is the combination of the tax payable for the year and the change during the year in deferred tax assets and liabilities.
	Earnings per share	Basic and diluted loss per common share have been computed by dividing the losses applicable to common stock by the weighted average number of common shares outstanding. The Company’s basic and fully diluted EPS calculation are the same since the increased number of shares that would be included in the diluted calculation from the assumed exercise of stock equivalents would be anti-dilutive to the net loss in each of the years shown in the financial statements.
	(“EPS”)
	Comprehensive income (loss)	Comprehensive income (loss) is defined as the change in equity during a period from transactions and other events and circumstances from non-owner sources. The Company is required to record all components of comprehensive income (loss) in the financial statements in the period in which they are recognized. Net income (loss) and other comprehensive income (loss), including unrealized gains and losses on investments, are reported net of their related tax effect, to arrive at comprehensive income (loss).
	Research and development costs	The Company is actively engaged in new product development efforts for which related costs are expensed as incurred.
	Fair value measurement	Financial assets and liabilities are measured at fair value, which is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. The following is a fair value hierarchy based on three levels of inputs, of which the first two are considered observable and the last unobservable, that may be used to measure fair value:
		•		Level 1—Quoted prices in active markets for identical assets or liabilities.
		•		Level 2—Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities, quoted prices in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.
		•		Level 3—Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.
	The following table presents the Company’s fair value hierarchy for assets and liabilities measured at fair value on a recurring basis as of June 30, 2014 and December 31, 2013 (in thousands):
		June 30, 2014									December 31, 2013
		Level 1			Level 2		Level 3		Total		Level 1		Level 2		Level 3		Total
	Assets:
	Cash and cash equivalents	$	34,565		$	—	$	—	$	34,565	$	51,804	$	—	$	—	$	51,804
	Short-term investments:
	Corporate debt securities
	Financial		—			27,532		—		27,532		—		—		—		—
	Industrial		—			6,265		—		6,265		—		—		—		—
	Utility		—			1,451		—		1,451		—		—		—		—
	Commercial paper
	Financial		—			5,591		—		5,591		—		—		—		—
	Industrial		—			—		—		—		—		—		—		—
	Total short-term investments	$	—		$	40,839	$	—	$	40,839	$	—	$	—	$	—	$	—
	Long-term investments:
	Corporate debt securities
	Financial		—			12,778		—		12,778		—		—		—		—
	Industrial		—			6,965		—		6,965		—		—		—		—
	Utility		—			—		—		—		—		—		—		—
	Total long-term investments	$	—		$	19,743	$	—		19,743	$	—	$	—	$	—	$	—
	Total assets measured at fair value	$	34,565		$	60,582	$	—	$	95,147	$	51,804	$	—	$	—	$	51,804
	Liabilities:
	Warrant liability		—			—		182		182		—		—		129		129
	Total liabilities measured at fair value	$	—		$	—	$	182	$	182	$	—	$	—	$	129	$	129
		The Company holds available-for-sale securities that consist of highly liquid, investment grade debt securities. The Company determines the fair value of its debt securities based upon one or more valuations reported by its investment accounting and reporting service provider. The investment service provider values the securities using a hierarchical security pricing model that relies primarily on valuations provided by an industry-recognized valuation service. Such valuations may be based on trade prices in active markets for identical assets or liabilities (Level 1 inputs) or valuation models using inputs that are observable either directly or indirectly (Level 2 inputs), such as quoted prices for similar assets or liabilities, yield curves, volatility factors, credit spreads, default rates, loss severity, current market and contractual prices for the underlying instruments or debt, and broker and dealer quotes, as well as other relevant economic measures.
		The Company used Level 3 inputs for its valuation methodology for the warrant derivative liabilities. The estimated fair values were determined using a binomial option pricing model based on various assumptions (see Note 9). The Company’s derivative liabilities are adjusted to reflect estimated fair value at each period end, with any decrease or increase in the estimated fair value being recorded in other income or expense accordingly, as adjustments to fair value of derivative liabilities.
	The following table presents the activity for liabilities measured at estimated fair value using unobservable inputs for the six months ended June 30, 2014:
	Fair Value Measurements Using Significant Unobservable Inputs (Level 3)
		Warrant Derivative
		Liability
	Beginning Balance at December 31, 2011	$	—
	Issuances		24,500
Ending Balance at December 31, 2012	$	24,500
Issuances		28,300
Adjustments to estimated fair value		76,600
Ending Balance at December 31, 2013	$	129,400
Adjustments to estimated fair value		52,400
Ending Balance at June 30, 2014	$	181,800

Reverse_Merger

Reverse Merger	6 Months Ended
	Jun. 30, 2014
Text Block [Abstract]	'
Reverse Merger	'
	2.      Reverse Merger	For purposes of the below descriptions in this Note 2, the PIPE financings and the 2011 Plan (each as defined below), all references to “Ignyta” shall refer to Ignyta, Inc., a Nevada corporation whose name was changed from Infinity Oil & Gas Company on October 31, 2013 in connection with the closing of the Merger; and all references to “Merger Sub” shall refer to IGAS Acquisition Corp., a Delaware corporation and a wholly owned subsidiary of Ignyta.
		On October 31, 2013, Ignyta, Merger Sub, and the Company entered into an Agreement and Plan of Merger and Reorganization (the “Merger Agreement”). The Merger Agreement provided for the merger of Merger Sub with and into the Company (the “Merger”), with the Company surviving the transaction as a wholly owned subsidiary of Ignyta. The Merger closed on October 31, 2013 concurrently with the execution and delivery of the Merger Agreement.
		Also on October 31, 2013, prior to the execution and delivery of the Merger Agreement and the concurrent closing of the Merger, (i) the holders of all series of outstanding preferred stock of the Company, consisting of Series A Preferred Stock and Series B Preferred Stock, voluntarily converted such shares into shares of the Company’s common stock in accordance with the certificate of incorporation of the Company and at the then-effective conversion rates therefor, which were one-to-one in all cases, and (ii) the Company amended its certificate of incorporation to change its name to “Ignyta Operating, Inc.” and to effect a three-to-one reverse stock split of its capital stock, resulting in 4,916,469 outstanding shares of the Company’s common stock, outstanding warrants to acquire up to an aggregate of 25,001 shares of the Company’s common stock, and outstanding options granted under the Company’s 2011 Stock Incentive Plan (as amended and restated, the “2011 Plan”) to purchase up to an aggregate of 358,986 shares of the Company’s common stock.
		At the closing of the Merger and pursuant to the terms of the Merger Agreement, Ignyta issued an aggregate of 4,916,469 shares of its common stock to the former stockholders of the Company in exchange for all of the outstanding shares of the Company’s capital stock. That number of shares was negotiated and agreed to by Ignyta and the Company prior to entering into the Merger Agreement. As of immediately following the closing of the Merger, the Company became a wholly-owned subsidiary of Ignyta, and the former stockholders of the Company collectively owned approximately 99.85% of the outstanding shares of Ignyta’s common stock. In addition, pursuant to the terms of the Merger Agreement, as of the closing of the Merger Ignyta assumed (i) the 2011 Plan, under which an aggregate of 342,209 shares were reserved for issuance pursuant to future equity grants, (ii) the obligation to issue up to an aggregate of 358,986 shares of its common stock upon the exercise of all options granted under the 2011 Plan that were outstanding as of immediately prior to the closing of the Merger, and (iii) the obligation to issue up to an aggregate of 25,001 shares of its common stock upon the exercise of two warrants previously issued by the Company and outstanding as of immediately prior to the closing of the Merger.
		On June 12, 2014, Ignyta merged with and into the Company, with the Company surviving the merger and changing its name to Ignyta, Inc. (the “Reincorporation Merger”). At the closing of the Reincorporation Merger, (i) each outstanding share of Ignyta’s common stock was converted into one share of common stock of the Company, (ii) each outstanding option to purchase, or other equity award relating to, Ignyta’s common stock was deemed to constitute an option to purchase, or other equity award relating to, common stock of the Company with no change in the exercise price or other terms or provisions of the award, (iii) the shares of Ignyta’s common stock that remained available for issuance under the 2011 Plan and the 2014 Incentive Award Plan (the “2014 Plan,” and, together with the 2011 Plan, the “Ignyta Plans”), were deemed to relate to shares of the Company’s common stock, and (iv) each outstanding warrant to purchase Ignyta’s common stock was deemed to constitute a warrant to purchase an equal number of shares of common stock of the Company with no change in the exercise price or other terms or provisions of the warrant.

Actagene_Merger

Actagene Merger	6 Months Ended
	Jun. 30, 2014
Business Combinations [Abstract]	'
Actagene Merger	'
	3.      Actagene Merger	In May 2013, the Company entered into an Agreement and Plan of Reorganization with Actagene. In accordance with the agreement, Actagene was merged into the Company and the separate corporate existence of Actagene ceased, with the Company continuing as the surviving corporation. On May 20, 2013, the merger was effected and the Company issued 1,583,336 shares of restricted common stock in exchange for the cancellation of all of the outstanding shares of Actagene.
		The merger was accounted for as a combination of entities under common control. The majority stockholder of the Company was also the majority stockholder of Actagene, with approximately 60% of the voting power in each entity. Additionally, representatives of the majority stockholder controlled the day to day operations and were on the board of directors of each entity.

Investments

Investments	6 Months Ended
	Jun. 30, 2014
Investments Schedule [Abstract]	'
Investments	'
	4.      Investments	The Company determines the appropriate designation of investments at the time of purchase and reevaluates such designation as of each balance sheet date. As of June 30, 2014, the Company’s short-term investments have maturity dates of less than one year from the balance sheet date. The Company’s long-term investments have maturity dates of greater than one year from the balance sheet date.
		The cost of securities sold is based on the specific identification method. Amortization of premiums, accretion of discounts, interest, dividend income, and realized gains and losses are included in investment income.
		The following table summarizes investments by security type as of June 30, 2014:
		June 30, 2014 (in thousands)
		Cost		Gross		Gross			Fair
				Unrealized		Unrealized			Market
				Gains		Losses			Value
	Available-for-sale securities:
	Corporate debt securities, short-term	$	40,840	$	—	$	(1	)	$	40,839
	Corporate debt securities, long-term	$	19,736	$	7	$	—		$	19,743
	Total	$	60,576	$	7	$	(1	)	$	60,582

Fixed_Assets

Fixed Assets	6 Months Ended
	Jun. 30, 2014
Property Plant And Equipment [Abstract]	'
Fixed Assets	'
	5.      Fixed Assets	Fixed assets consisted of the following:
		June 30,			December 31,
		2014			2013
	Manufacturing and lab equipment	$	2,337,895		$	775,872
	Office furniture		115,461			59,095
	Computers and equipment		168,375			110,857
	Leasehold Improvements		133,067			—
			2,754,798			945,824
	Less accumulated depreciation and amortization		(225,569	)		(115,118	)
		$	2,529,229		$	830,706
		Depreciation expense for three months ended June 30, 2014 and 2013 was $63,108 and $27,514, respectively, and for the six months ended June 30, 2014 and 2013 and for the period from inception (August 29, 2011) through June 30, 2014 was $111,708, $48,077, and $237,980, respectively.

Notes_Payable

Notes Payable	6 Months Ended
	Jun. 30, 2014
Debt Disclosure [Abstract]	'
Notes Payable	'
	6.      Notes Payable	On December 31, 2013 the Company entered into an amended and restated loan and security agreement (the “New Loan Agreement”) with a financial institution. The New Loan Agreement replaced the prior loan and security agreement (the “Loan Agreement”) which was first entered into in June 2012 and amended in February 2013. The maximum borrowing amount under the New Loan Agreement was increased from $1,500,000 to $10,000,000. All principal and interest due on the prior Loan Agreement was paid in full and the Company was advanced the net proceeds on December 31, 2013. Payments of principal and interest are due on the New Loan Agreement on a fully amortized basis of 36 months in equal monthly installments, commencing after a twelve-month period of interest only payments, such that all amounts owed under the New Loan Agreement will mature on December 1, 2017. Upon such maturity date, the Company will also owe to the lender a final payment of $1,050,000, equal to 10.50% of the full principal amount under the New Loan Agreement. The final payment of $1,050,000 is presented as a debt discount on the related debt to be amortized to interest expense. Interest on the $10,000,000 note was fixed on the date of funding at 6.92%. The loan is collateralized by substantially all of the assets of the Company, other than its intellectual property.
		As additional consideration for the cost and risk associated with the Loan Agreement, the Company issued to the lender a warrant to purchase up to 8,334 shares of Series B Preferred Stock in June 2012, and an additional warrant to purchase up to a number of shares of Series B Preferred Stock equal to 5% of the amount loaned under the Loan Agreement on February 27, 2013 and thereafter, subject to adjustment as set forth in the warrant, including without limitation for stock combinations and splits. As a result, following the final advance under the Loan Agreement in July 2013, the warrant became exercisable for 16,667 shares of the Company’s Series B Preferred Stock. The warrants issued in 2013 and 2012 were recorded at fair values of $28,300 and $24,500, respectively, and were presented as a debt discount on the related debt to be amortized to interest expense over the term of the Loan Agreement (See Note 9). Both warrants were assumed by Ignyta in connection with the Merger (see Note 2). No new warrants were issued in conjunction with the New Loan Agreement, and as a result of the payoff of the original loan, the debt discount was written off on December 31, 2013.
		Interest expense due to amortization of the debt discount for the three months ended June 30, 2014 and 2013 was $73,102 and $3,367, respectively, and for the six months ended June 30, 2014 and 2013 and for the period from inception (August 29, 2011) through June 30, 2014 was $147,463, $5,494 and $200,263, respectively.
		Future minimum principal payments on notes payable are as follows:
	Twelve Months ending June 30,
	2015	$	1,525,442
	2016		3,212,403
	2017		3,446,423
	2018		1,815,732
	Total	$	10,000,000

Stockholders_Equity

Stockholders' Equity	6 Months Ended
	Jun. 30, 2014
Equity [Abstract]	'
Stockholders' Equity	'
	7.      Stockholders’ Equity	The Company is authorized to issue 150,000,000 shares of common stock and 10,000,000 shares of preferred stock, with the preferred stock having the rights, preferences and privileges that our Board of Directors may determine from time to time. Each share of the Company’s common stock is entitled to one vote, and all shares rank equally as to voting and other matters.
		On March 19, 2014, the Company completed a secondary public stock offering providing for the issuance and sale to investors of an aggregate of 6,031,750 shares of its common stock at a purchase price of nine dollars and fifteen cents ($9.15) per share for gross proceeds of approximately $55.2 million.
		On November 29, 2013, the Company completed a PIPE financing with 195 accredited investors, providing for the issuance and sale to such investors of an aggregate of 1,270,096 shares of its common stock at a purchase price of six dollars ($6.00) per share, for gross proceeds of approximately $7.6 million.
		On November 6, 2013, the Company completed a PIPE financing, providing for the issuance and sale of an aggregate of 7,740,142 shares of its common stock to 52 accredited investors at a purchase price of six dollars ($6.00) per share, for gross proceeds of approximately $46.4 million.
		On October 31, 2013, Ignyta, Inc. approved a 100-for-1 reverse stock split of its capital stock, and the Company approved a 3-for-1 reverse stock split of its capital stock (the “Reverse Stock Splits”). The par value of Ignyta, Inc.’s outstanding capital stock changed from $0.0001 to $0.00001 per share on such date. At the closing of the Reincorporation Merger, the par value of the Company’s outstanding capital stock changed back from $0.00001 to $0.0001 per share. The stockholders’ equity section of the accompanying financial statements and all share numbers disclosed throughout the financial statements have been retroactively adjusted to give effect to the Reverse Stock Splits and the Reincorporation Merger.
	Series A Convertible Preferred Stock	During 2012, the Company issued 416,667 shares of Series A Preferred Stock at $0.60 per share for proceeds consisting of $250,000 in cash.
		During 2011, the Company issued 416,667 shares of Series A Preferred Stock at $0.60 per share for proceeds consisting of $250,000 in cash.
		On October 31, 2013, prior to the Reverse Stock Splits, the holders of shares of the Company’s Series A Preferred Stock elected to convert all issued and outstanding shares of such preferred stock into shares of common stock at the applicable conversion rate, which was one-to-one.
	Series B Convertible Preferred Stock	During 2012, the Company issued 1,835,000 shares of Series B Preferred Stock at $3.00 per share for proceeds consisting of $5,505,000 in cash.
		On October 31, 2013, prior to the Reverse Stock Splits, the holders of shares of the Company’s Series B Preferred Stock elected to convert all issued and outstanding shares of such preferred stock into shares of common stock at the applicable conversion rate, which was one-to-one.

StockBased_Compensation

Stock-Based Compensation	6 Months Ended
	Jun. 30, 2014
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]	'
Stock-Based Compensation	'
	8.      Stock-Based Compensation	On June 11, 2014, the Company adopted the 2014 Plan. The 2014 Plan provides for the issuance of equity awards to employees and non-employees of 3,000,000 shares, plus one share for each share subject to a stock option that was outstanding under the 2011 Plan as of the effective date of the 2014 Plan that subsequently expires, is forfeited or is settled in cash.
		On February 28, 2014, the Company adopted the Employment Inducement Incentive Award Plan (the “Inducement Plan”). The Inducement Plan provided for the issuance of equity awards to new employees of 1,000,000 shares.
		In 2011, the Company adopted the 2011 Plan. The 2011 Plan provided for the issuance of incentive stock options to employees and nonstatutory stock options, restricted stock awards, stock appreciation rights and stock bonuses to directors, employees and consultants. In February 2013, October 2013 and December 2013, the 2011 Plan was amended to, among other things, increase the number of shares of the Company’s common stock available for issuance thereunder from 166,666 shares to 666,666 shares, to 712,652 shares and to 2,712,652 shares, respectively.
	Stock option activity	There are a total of 3,000,000 shares of common stock reserved under the 2014 Plan, plus one share for each share subject to a stock option that was outstanding under the 2011 Plan as of the effective date of the 2014 Plan that subsequently expires, is forfeited or is settled in cash. As of June 30, 2014, 2,910,000 shares remain available under the 2014 Plan. There were a total of 2,712,652 shares of common stock reserved under the 2011 Plan. As of June 30, 2014, 1,607,071 shares remained available; however, under applicable rules of the NASDAQ Stock Market, the Company may not make additional grants under the 2011 Plan unless the 2011 Plan is approved by the Company’s stockholders. The Company did not seek stockholder approval and adopted the 2014 Plan. In addition, there were 1,000,000 shares of common stock reserved under the Inducement Plan. As of June 30, 2014, 190,000 shares remained available under the Inducement Plan. From and after the effective date of the 2014 Plan, no additional equity grants may be made by the Company under the 2011 Plan or the Inducement Plan.
		At the closing of the Reincorporation Merger, (i) each outstanding option to purchase, or other equity award relating to, Ignyta’s common stock was deemed to constitute an option to purchase, or other equity award relating to, common stock of the Company with no change in the exercise price or other terms or provisions of the award, and (ii) the shares of Ignyta’s common stock that remained available for issuance under the Ignyta Plans were deemed to relate to shares of the Company’s common stock.
		The options that are granted under the Ignyta Plans and the Inducement Plan are exercisable at various dates and will expire no more than ten years from their dates of grant. The exercise price of each option to be granted under the 2014 Plan shall be determined by the administrator of the 2014 Plan, which is the Company’s Board of Directors or the Compensation Committee thereof, and shall not be less than 100% of the fair market value of the Company’s common stock on the date the option is granted. Generally, options are granted with an exercise price equal to the fair market value of the Company’s common stock on the date of the option grant. For holders of more than 10% of the Company’s total combined voting power of all classes of stock, incentive stock options may not be granted at less than 110% of the fair market value of the Company’s common stock on the date of grant and for a term not to exceed five years.
		A summary of the Company’s stock option activity and related information is as follows:
		Options			Weighted-			Weighted-		Aggregate
		Outstanding			Average			Average		Intrinsic
					Exercise			Remaining		Value
					Price			Contractual
								Term
	Balance at December 31, 2011		12,500		$	0.18			—	$	—
	Granted		144,159			0.39			—		—
	Exercised		—			—			—		—
	Cancelled		—			—			—		—
	Balance at December 31, 2012		156,659			0.36			—		—
	Granted		1,061,325			4.6			—		—
	Exercised		(12,290	)		0.24			—		—
	Expired		(2,154	)		0.54			—		—
	Forfeited		(70,387	)		0.45			—		—
	Balance at December 31, 2013		1,133,153		$	4.33			9.71	$	3,026,430
	Granted		1,442,000			8.02			—		—
	Exercised		(12,962	)		0.42			—		—
	Expired		(4,999	)		0.58			—		—
	Forfeited		(237,036	)		7.68			—		—
	Balance at June 30, 2014		2,320,156		$	6.31			9.56	$	6,457,975
	Exercisable at June 30, 2014		135,838		$	0.67			8.51	$	1,144,042
		The fair value of options granted to employees and non-employee directors was estimated at the date of grant using a Black-Scholes option pricing model with the weighted-average assumptions stated below.
		Three			Three
		Months			Months
		Ended			Ended
		June 30,			June 30,
		2014			2013
	Risk free interest rate		1.76	%		0	%
	Dividend yield		0	%		0	%
	Volatility		68.36	%		0	%
	Weighted-average expected life of option (years)		6			0
		Six			Six
		Months			Months
		Ended			Ended
		June 30,			June 30,
		2014			2013
	Risk free interest rate		1.83	%		1.18	%
	Dividend yield		0	%		0	%
	Volatility		63.83	%		59.82	%
	Weighted-average expected life of option (years)		6.02			5.99
		The estimated weighted-average per-share fair value of stock options granted to employees and non-employee directors for the three months ended June 30, 2014 and 2013 was $4.51 and $0.00, respectively and for the six months ended June 30, 2014 and 2013 was $4.70 and $0.33, respectively.
		The fair value of options granted to non-employees was estimated at the vesting date using a Black-Scholes option pricing model with the weighted-average assumptions stated below.
		Three			Three
		Months			Months
		Ended			Ended
		June 30,			June 30,
		2014			2013
	Risk free interest rate		2.52	%		0	%
	Dividend yield		0	%		0	%
	Volatility		68.42	%		0	%
	Weighted-average expected life of option (years)		9.95			0
		The fair value of options granted to non-employees was estimated at the vesting date using a Black-Scholes option pricing model with the weighted-average assumptions stated below.
		Six			Six
		Months			Months
		Ended			Ended
		June 30,			June 30,
2014		2013
Risk free interest rate		2.5	%		2.05	%
Dividend yield		0	%		0	%
Volatility		68.37	%		59.25	%
Weighted-average expected life of option (years)		9.85			10
	The estimated weighted-average per-share fair value of stock options granted to non-employees for the three months ended June 30, 2014 and 2013 was $6.94 and $0.00, respectively, and for the six months ended June 30, 2014 and 2013 was $6.65 and $0.42, respectively.
	Dividend Yield—The Company has never declared or paid dividends on common stock and has no plans to do so.
	Expected Volatility—Volatility is a measure of the amount by which a financial variable such as a share price has fluctuated or is expected to fluctuate during a period. The Company considered the historical volatility of peer companies and business and economic considerations in order to estimate the expected volatility, due to the Company not being publicly traded for a significant period.
	Risk-Free Interest Rate—This is the U.S. Treasury rate for the day of each option grant during the quarter having a term that most closely resembles the expected life of the option.
	Expected Life of the Option Term—This is the period of time that the options granted are expected to remain unexercised. Options granted during the period have a maximum contractual term of ten years. The Company estimates the expected life of the option term based on the simplified method as defined in Staff Accounting Bulletin 110. For non-employee options granted, this is the remaining contractual term of the option as of the reporting date.
	Forfeitures are estimated at the time of grant and revised, if necessary, in subsequent periods if actual forfeitures differ from those estimates. The Company assesses the forfeiture rate on an annual basis and revises the rate when deemed necessary.
	Stock-based compensation expense for employees and non-employees for the three months ended June 30, 2014 and 2013 was $346,040 and $16,602, respectively, and for the six months ended June 30, 2014 and 2013 and the period from inception (August 29, 2011) through June 30, 2014 was $661,146, $38,986 and $1,025,759, respectively. For the three months ended June 30, 2014 and 2013, $99,791 and $9,884 was recorded to research and development expense, respectively, and $246,249 and $6,719 was recorded to general and administrative expense, respectively. For the six months ended June 30, 2014 and 2013 and the period from inception (August 29, 2011) through June 30, 2014, $153,259, $29,304 and $380,992 was recorded to research and development expense, respectively, and $507,887, $9,682, and $644,767 was recorded to general and administrative expense, respectively.
	As of June 30, 2014, there was an additional $8,000,700 of total unrecognized compensation cost related to unvested stock-based awards granted under the Ignyta Plans and the Inducement Plan. This unrecognized compensation cost is expected to be recognized over a weighted-average period of 3.57 years.
Restricted stock activity	In 2011, Ignyta sold 666,668 shares of restricted common stock for gross proceeds of $2,000 in accordance with restricted stock purchase agreements with various advisors. Approximately 600,000 shares were vested immediately and the remaining 66,668 are subject to vesting requirements based on future service.
	The terms of each of the agreements state that the Company has the right to repurchase the unvested shares of stock if the shareholder stops providing services to the Company. The Company repurchased 13,334 shares of common stock in 2012. The Company records stock-based compensation expense, calculated as the difference between the fair value of the common stock at each reporting period less the proceeds received, upon vesting of the restricted stock. Related stock-based compensation for the three months ended June 30, 2014 and 2013 was $18,180 and $2,040, respectively, and for the six months ended June 30, 2014 and 2013 and the period from inception (August 29, 2011) through June 30, 2014 was $34,780, $3,240 and $64,760, respectively. All stock-based compensation relating to restricted stock was expensed to research and development. At June 30, 2014, 635,334 shares were vested and 18,000 shares remained unvested.
	On May 20, 2013, in connection with Ignyta’s merger with Actagene, Ignyta issued 1,583,336 shares of restricted common stock in exchange for the cancellation of all of the outstanding shares of Actagene (see Note 3). In February of 2014, in connection with the termination of employment of an employee, the Company repurchased 400,000 restricted shares. Of the remaining restricted shares, approximately 1,000,000 shares were vested immediately and 183,336 are subject to vesting requirements based on future service. The shares vest over four years, with one-third having vested in February 2014 and the remaining unvested shares vesting over the next 36 months. Related stock-based compensation for the three months ended June 30, 2014 and 2013 was $16,831 and $0, respectively, and for the six months ended June 30, 2014 and 2013 and the period from inception (August 29, 2011) through June 30, 2014 was $121,404, $0 and $121,404, respectively. All stock-based compensation relating to restricted stock was expensed to research and development. At June 30, 2014, 1,133,952 shares were vested and 49,384 shares remained unvested.
	All of the foregoing restricted stock was exchanged for shares of Ignyta, Inc. common stock in connection with the Merger and for the Company’s common stock in connection with the Reincorporation Merger (see Note 2).

Warrants

Warrants	6 Months Ended
	Jun. 30, 2014
Derivative Instruments And Hedging Activities Disclosure [Abstract]	'
Warrants	'
	9.      Warrants	On November 6, 2013, the Company issued Nerviano Medical Sciences S.r.l. (“NMS”) a warrant to acquire up to 16,667 shares of its common stock in connection with the license agreement between the Company and NMS. The warrant has an exercise price of $6.00 per share and is exercisable at the option of the holder, in whole or in part, at any time until November 6, 2018. The terms of such warrant provide for adjustments in the event of certain stock dividends, stock splits, recapitalizations, reclassifications and consolidations. Upon exercise, the aggregate exercise price of the warrant issued is payable by NMS in cash.
		The Company recognized warrant expense of $47,600 using a binomial model with an exercise price of $6.00, risk free interest rate of 1.68%, volatility of 54.8%, and a useful life of 4.85 years. The entire amount was expensed to research and development in 2013.
		During 2012, the Company issued a warrant to purchase 8,334 shares of Series B Preferred Stock in connection with the Loan Agreement (see Note 6). The exercise price of the warrant is $3.00 per share.
		On February 27, 2013, the Company issued a warrant to purchase up to a number of shares of Series B Preferred Stock equal to 5% of the amount loaned under the Loan Agreement on February 27, 2013 and thereafter, subject to adjustment as set forth in the warrant, including without limitation for stock combinations and splits (see Note 6). As a result, following the February 2013 and July 2013 advances under the Loan Agreement, the warrant became exercisable for 16,667 shares of the Company’s Series B Preferred Stock. The exercise price of the warrant is $3.00 per share and the warrant expires February 27, 2020.
		The exercise price of the warrants issued in conjunction with the loan financing is protected against dilutive financing through the term of the warrants. Pursuant to ASC 815-15 and ASC 815-40, the fair value of the warrants was recorded as a derivative liability on the issuance dates.
		Each of the warrants was valued at the grant date and at the end of each reporting period thereafter.
		The Company revalued all of the warrants at the end of each reporting period, and the estimated fair value of the outstanding warrant liability was $181,800 and $30,900 at June 30, 2014 and 2013, respectively. The change in the estimated fair value of the derivative liability resulted in other expense of $52,400 for the six month period ended June 30, 2014 and other income of $5,700 for the six month period ended June 30, 2013.
		The derivative liabilities were valued at their issuance dates and at the end of each reporting period using a binomial pricing model and the following weighted average assumptions:
		June 30, 2014			June 30, 2013
	Expected volatility		69.5	%		39.6	%
	Risk-free interest rate		1.77	%		1.69	%
	Dividend yield		0	%		0	%
	Remaining expected term of underlying securities (years)		5.57			6.67

Income_Taxes

Income Taxes	6 Months Ended
	Jun. 30, 2014
Income Tax Disclosure [Abstract]	'
Income Taxes	'
	10.    Income Taxes	The Company maintains deferred tax assets that reflect the net tax effects of temporary differences between the book values of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. These deferred tax assets include net operating loss carryforwards, deferred revenue and stock-based compensation. In assessing the potential for realization of deferred tax assets, the Company considers whether it is more likely than not that some or all of the deferred tax assets will not be realized.
		The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during periods in which those temporary differences become deductible. The Company considers projected future taxable income and planning strategies in making this assessment. Based on the level of historical operating results and projections for the taxable income for the future, the Company has determined that it is more likely than not that the deferred tax assets will not be realized. Accordingly, the Company has recorded a valuation allowance to reduce deferred tax assets to zero. The Company may not ever be able to realize the benefit of some or all of the federal and state loss carryforwards, either due to ongoing operating losses or due to ownership changes, which limit the usefulness of the loss carryforwards.

Commitments_and_Contingencies

Commitments and Contingencies	6 Months Ended
	Jun. 30, 2014
Commitments And Contingencies Disclosure [Abstract]	'
Commitments and Contingencies	'
	11.    Commitments and Contingencies
	Operating leases	The Company leases office space under non-cancelable operating leases expiring on various dates through October 2019. Rent expense under those operating leases for the three months ended June 30, 2014 and 2013 was $111,204 and $41,081, respectively, and for the six months ended June 30, 2014 and 2013, and for the period from inception (August 29, 2011) through June 30, 2014 was $158,680, $59,382 and $335,551, respectively.
		The Company leases lab equipment under a non-cancelable operating lease that expires in March 2016. Monthly payments are $5,758. Rent expense under that operating lease for the three months ended June 30, 2014 and 2013 was $22,126 and $16,368, respectively, and for the six months ended June 30, 2014 and 2013, and for the period from inception (August 29, 2011) through June 30, 2014 was $44,252, $16,368 and $104,872, respectively.
		Future minimum lease payments required under the operating leases are as follows:
	Twelve Months Ending June,
	2015	$	475,500
	2016		788,300
	2017		758,600
	2018		781,300
	2019		804,700
	Thereafter		274,900
	Total	$	3,883,300
	License agreements	The Company has entered into a license agreement with NMS which became effective on November 6, 2013, whereby the Company obtained an exclusive license in certain of NMS’ Active Pharmaceutical Ingredients (APIs) and certain NMS IP rights upon the effective date of the agreement. An initial payment of $7,000,000 was paid in November 2013. The entire amount was expensed to research and development in 2013 as no future benefit can be determined at this time. In addition, NMS was issued on November 6, 2013 a five year warrant to purchase 16,667 shares of our common stock at an exercise price per share of six dollars ($6.00). Tiered royalties in the low single digits to mid double digits will be paid based upon aggregate annual net sales. The agreement also requires that the Company makes development and regulatory milestone payments to NMS of up to $105.0 million in the aggregate if specified clinical study initiations and regulatory approvals are achieved across multiple products or indications. The first such milestone payment is not due until the Company elects to initiate the first randomized Phase II clinical study, which, based on its current estimates and certain assumptions, the Company anticipates could occur as early as 2015. The Company is obligated under the terms of the license agreement to engage NMS to perform services valued at $1 million or more between the effective date of the license agreement and December 31,
		2014, which services could include, among others at the Company’s election, manufacture and supply services, technology transfer activities, preclinical activities, process development activities and assay development activities. As of June 30, 2014, this obligation was fully met.
		In March 2012, the Company entered into a license agreement with a university for the use of certain patented rights relating to molecular diagnostics. The Company delivered notice to the university of the Company’s exercise of its right to terminate the license agreement, effective as of April 2014. Under the agreement, the Company was required to make annual license payments of $15,000. The Company made the first license payment under the agreement in 2012 and its annual license payment under the agreement in 2013. These payments were amortized monthly and expensed to research and development.
		On March 31, 2014, the Company entered into an agreement with a contract research organization for clinical studies to be conducted both within and outside the U.S., at an estimated cost of approximately $10 million over a two-year period.

Concentrations

Concentrations	6 Months Ended
	Jun. 30, 2014
Text Block [Abstract]	'
Concentrations	'
	12.    Concentrations
	Credit risk	The Company maintains cash balances at various financial institutions. Accounts at these institutions are secured by the Federal Deposit Insurance Corporation. At times these balances exceed federally insured limits. The Company has not experienced any losses in such accounts.
		With respect to our available-for-sale securities, our primary exposure to market risk is interest rate sensitivity. This means that a change in prevailing interest rates may cause the value of the investment to fluctuate. For example, if we purchase a security that was issued with a fixed interest rate and the prevailing interest rate later rises, the value of our investment will probably decline. Currently, our holdings are in money market funds and available-for-sale securities, and therefore this interest rate risk is minimal. To minimize our interest rate risk going forward, we intend to continue to maintain our portfolio of cash, cash equivalents and available-for-sale securities in a variety of securities consisting of money market funds and debt securities, all with various maturities. In general, money market funds are not subject to market risk because the interest paid on such funds fluctuates with the prevailing interest rate. We also generally time the maturities of our investments to correspond with our expected cash needs, allowing us to avoid realizing any potential losses from having to sell securities prior to their maturities.
		Our cash is invested in accordance with a policy approved by our Board of Directors which specifies the categories, allocations, and ratings of securities we may consider for investment. We do not believe our cash, cash equivalents and available-for-sale securities have significant risk of default or illiquidity. We made this determination based on discussions with our treasury managers and a review of our holdings. While we believe our cash, cash equivalents and available-for-sale securities are well diversified and do not contain excessive risk, we cannot provide absolute assurance that our investments will not be subject to future adverse changes in market value.

Related_Parties

Related Parties	6 Months Ended
	Jun. 30, 2014
Related Party Transactions [Abstract]	'
Related Parties	'
	13.    Related Parties	In 2012, the Company executed an employee lease agreement with its majority stockholder. Under the terms of the agreement, the Company is reimbursed for certain administrative services provided to the related party. In addition, the Company was reimbursed for various operating expenses related to shared utilities and telecommunications and/or may make payments to its majority shareholder for these shared operating expenses.
		Total reimbursements received during the three months ended June 30, 2014 and 2013 was $0 and $95, respectively, and for the six months ended June 30, 2014 and 2013 and the period from inception (August 29, 2011) through June 30, 2014 was $0, $5,372 and $19,397, respectively. There was $0 in accounts receivable at June 30, 2014 and 2013, respectively. Total payments made during the three months ended June 30, 2014 and 2013 was $453 and $19,241, respectively, and for the six months ended June 30, 2014 and 2013 and the period from inception (August 29, 2011) through June 30, 2014 was $1,165, $22,409 and $40,215, respectively.
		In May 2013, the Company and Actagene effected a merger pursuant to which Actagene merged with and into the Company. The majority stockholder of Ignyta was also the majority stockholder of Actagene, and representatives of the majority stockholder controlled the day to day operations and were on the board of directors of each entity (see Note 3).

401k_Plan

401(k) Plan	6 Months Ended
	Jun. 30, 2014
Postemployment Benefits [Abstract]	'
401(k) Plan	'
	14.    401(k) Plan	In 2014, the Company established a defined contribution plan, organized under Section 401(k) of the
		Internal Revenue Code, which allows employees who have completed at least one month of service and have reached age 21 to defer up to 100% of their pay on a pre-tax basis. The Company does not contribute a match to the employees’ contribution

Subsequent_Events

Subsequent Events	6 Months Ended
	Jun. 30, 2014
Subsequent Events [Abstract]	'
Subsequent Events	'
	15.    Subsequent Events	On August 4, 2014, the Company entered into a license agreement with NMS granting the Company an exclusive license to two new drug development programs, which the Company will refer to as RXDX-103 and RXDX-104, and related intellectual property. Under the license agreement, the Company will make an initial payment to NMS of $3.5 million by August 14, 2014. Tiered royalties in the mid-single digits to low double digits will be paid based upon aggregate annual net sales. The agreement also requires that the Company makes development and regulatory milestone payments to NMS of up to $102.0 million in the aggregate if specified clinical study initiations and regulatory approvals are achieved across multiple products or indications.

Summary_of_Significant_Account1

Summary of Significant Accounting Policies (Policies)	6 Months Ended
	Jun. 30, 2014
Accounting Policies [Abstract]	'
Nature of operations	'
	Nature of operations	Ignyta, Inc. (“Ignyta”) was founded in 2011 and is incorporated in the state of Delaware. On June 11, 2014, Ignyta, Inc. merged with and into Ignyta Operating, Inc. with Ignyta Operating, Inc. surviving the merger and changing its name to Ignyta, Inc.
		On October 31, 2013, Ignyta merged with and into IGAS Acquisition Corp., a wholly-owned subsidiary of Ignyta, Inc., a Nevada corporation previously named Infinity Oil & Gas Company (see Note 2). As used in these financial statements, unless the context indicates or otherwise requires, the “Company”, “we”, “us”, and “our” refer to Ignyta.
		In May 2013, Ignyta acquired Actagene Oncology, Inc. (“Actagene”), a San Diego based privately held biotechnology company developing precision medicines for high unmet need cancer indications, based on cancer genome mining and sequencing. With the acquisition, Ignyta changed its business strategy from a prior focus on molecular diagnostics for autoimmune disease to an integrated drug and diagnostic, or Rx/Dx, focus on drug and biomarker discovery and development for oncology (see Note 3).
		The Company is a precision medicine biotechnology company dedicated to discovering or acquiring, then developing and commercializing, precisely targeted new drugs for cancer patients whose tumors harbor specific molecular alterations. The Company pursues an Rx/Dx strategy, where it aims to pair each of its innovative drugs with biomarker-based companion diagnostics, developed by the Company or by third parties with which it may partner, that are designed to identify the patients that are most likely to benefit from the use of the drugs that the Company may develop.
Basis of Presentation	'
	Basis of Presentation	The accompanying unaudited condensed financial statements have been prepared in accordance with U.S. generally accepted accounting principles (“GAAP”) for interim financial information, the instructions to Form 10-Q and related Securities and Exchange Commission (“SEC”) rules and regulations. Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. In management’s opinion, the accompanying financial statements reflect all adjustments, consisting of normal recurring adjustments, considered necessary for a fair presentation of the results for the interim periods presented.
		Interim financial results are not necessarily indicative of results anticipated for the full year. These unaudited financial statements should be read in conjunction with the Company’s audited financial statements and footnotes included in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2013, from which the balance sheet information herein was derived.
		The preparation of financial statements requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenue and expenses, and related disclosure of contingent assets and liabilities. Actual results could differ from those estimates.
Development stage	'
	Development stage	As of June 30, 2014, the Company has devoted substantially all of its efforts to product development, raising capital and building infrastructure, and has not realized revenues from its planned principal operations. Accordingly, the Company is considered to be in the development stage.
Liquidity	'
	Liquidity	As of June 30, 2014, the Company had an accumulated deficit of approximately $25,102,000. The Company also had negative cash flow from operations of approximately $6,252,000 during the six months ended June 30, 2014.
		The Company expects that it will need additional capital to further fund development of, and seek regulatory approvals for, its product candidates, and begin to commercialize any approved products.
		We are currently focused primarily on the development of our RXDX-101, Spark-1, Spark-2 and Spark-3 programs, and we intend to devote resources to our newly-licensed RXDX-103 and RXDX-104 programs. We believe such activities will result in our continued incurrence of significant research and development and other expenses related to those programs. If the clinical trials for any of our products fail or produce unsuccessful results and those product candidates do not gain regulatory approval, or if any of our product candidates, if approved, fails to achieve market acceptance, we may never become profitable. Even if we achieve profitability in the future, we may not be able to sustain profitability in subsequent periods. The Company intends to cover its future operating expenses through cash on hand and through additional financing from existing and prospective investors. We cannot be sure that additional financing will be available when needed or that, if available, financing will be obtained on terms favorable to us or to our stockholders.
		While we expect that our existing cash and cash equivalents will enable us to fund our operations and capital expenditure requirements for at least the next twelve months, having insufficient funds may require us to delay, reduce, or eliminate some or all of our development programs. Failure to obtain adequate financing could eventually adversely affect our ability to operate as a going concern. If we raise additional funds from the issuance of equity securities, substantial dilution to our existing stockholders would likely result. If we raise additional funds by incurring debt financing, the terms of the debt may involve significant cash payment obligations as well as covenants and specific financial ratios that may restrict our ability to operate our business.
Use of estimates	'
	Use of estimates	The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenue and expenses, and related disclosure of contingent assets and liabilities. Actual results could differ from those estimates. Significant estimates used in preparing the financial statements include those assumed in computing the valuation allowance on deferred tax assets and the valuation of warrants, and those assumed in calculating stock-based compensation expense.
Cash and cash equivalents	'
	Cash and cash equivalents	The Company considers all highly liquid investments with an original maturity of 90 days or less when purchased to be cash equivalents. Cash equivalents primarily represent amounts invested in money market funds whose cost equals market value.
Investments	'
	Investments	Investments consist of corporate notes and bonds and commercial paper. The Company classifies investments as available-for-sale at the time of purchase. All investments are recorded at estimated fair value. Unrealized gains and losses for available-for-sale securities are included in accumulated other comprehensive income, a component of stockholders’ equity. The Company evaluates its investments as of each balance sheet date to assess whether those with unrealized loss positions are other-than-temporarily impaired. Impairments are considered to be other-than-temporary if they are related to deterioration in credit risk or if it is likely that the Company will sell the securities before the recovery of its cost basis. Realized gains and losses and declines in value judged to be other-than-temporary are determined based on the specific identification method and are reported in other income (expense), net in the Statements of Operations. No other-than-temporary impairment charges were recognized in the three and six months ended June 30, 2014 or in the fiscal years ended December 31, 2013, 2012 and 2011.
Fixed assets	'
	Fixed assets	Fixed assets are recorded at cost. Depreciation is computed using the straight-line method over the estimated useful lives of the related assets, generally three to five years, or, in the case of leasehold improvements, over the lesser of the useful life of the related asset or the lease term.
Impairment of long-lived assets	'
	Impairment of long-lived assets	In accordance with authoritative guidance related to impairment or disposal of long-lived assets, management reviews the Company’s long-lived asset groups for impairment whenever events indicate that their book value may not be recoverable. When management determines that one or more impairment indicators are present for an asset group, it compares the book value of the asset group to net future undiscounted cash flows that the asset group is expected to generate. If the book value of the asset group is greater than the net future undiscounted cash flows that the asset group is expected to generate, it compares the fair value to the book value of the asset group. If the fair value is less than the book value, it recognizes an impairment loss. The impairment loss would be the excess of the book value of the asset group over its fair value. To date, the Company has not experienced any impairment losses on its long-lived assets used in operations.
Stock-based compensation	'
	Stock-based compensation	The Company accounts for stock-based compensation in accordance with Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) Topic 718, Compensation—
		Stock Compensation, which establishes accounting for equity instruments exchanged for employee services. Under such provisions, stock-based compensation cost is measured at the grant date, based on the calculated fair value of the award, and is recognized as an expense, under the straight-line method, over the employee’s requisite service period (generally the vesting period of the equity grant).
		The Company accounts for equity instruments, including restricted stock or stock options, issued to non-employees in accordance with authoritative guidance for equity based payments to non-employees. Stock options issued to non-employees are accounted for at their estimated fair value determined using the Black-Scholes option-pricing model. The fair value of options granted to non-employees is re-measured as they vest, and the resulting increase in value, if any, is recognized as expense during the period the related services are rendered. Restricted stock issued to non-employees is accounted for at its estimated fair value as it vests.
Fair value of financial instruments	'
	Fair value of financial instruments	The Company’s financial instruments consist of cash and cash equivalents, investments, prepaid expenses and other assets, accounts payable, accrued expenses, and notes payable. Fair value estimates of these instruments at a specific point in time are made based on relevant market information. These estimates may be subjective in nature and involve uncertainties and matters of significant judgment and therefore cannot be determined with precision. As of June 30, 2014 and December 31, 2013, the book values are generally considered to be representative of their respective fair values because of the short-term nature of those instruments.
Derivative liabilities	'
	Derivative liabilities	The Company accounts for its warrants as either equity or liabilities based upon the characteristics and provisions of each instrument. Warrants classified as derivative liabilities are recorded on the Company’s balance sheet at their fair value on the date of issuance and revalued on each subsequent balance sheet date until such instruments are exercised or expire, with any changes in the fair value between reporting periods recorded as other income or expense. Management estimates the fair value of these liabilities using option pricing models and assumptions that are based on the individual characteristics of the warrants or instruments on the valuation date, as well as assumptions for future events, expected volatility, expected life, yield, and risk free interest rate.
Income taxes	'
	Income taxes	Deferred income taxes are recognized for the tax consequences in future years of differences between the tax basis of assets and liabilities and their financial reporting amounts at each year end based on enacted tax laws and statutory tax rates applicable to the periods in which the differences are expected to affect taxable income. Valuation allowances are established when necessary to reduce deferred tax assets to the amount expected to be realized. Income tax expense is the combination of the tax payable for the year and the change during the year in deferred tax assets and liabilities.
Earnings per share ("EPS")	'
	Earnings per share (“EPS”)	Basic and diluted loss per common share have been computed by dividing the losses applicable to common stock by the weighted average number of common shares outstanding. The Company’s basic and fully diluted EPS calculation are the same since the increased number of shares that would be included in the diluted calculation from the assumed exercise of stock equivalents would be anti-dilutive to the net loss in each of the years shown in the financial statements.
Comprehensive income (loss)	'
	Comprehensive income (loss)	Comprehensive income (loss) is defined as the change in equity during a period from transactions and other events and circumstances from non-owner sources. The Company is required to record all components of comprehensive income (loss) in the financial statements in the period in which they are recognized. Net income (loss) and other comprehensive income (loss), including unrealized gains and losses on investments, are reported net of their related tax effect, to arrive at comprehensive income (loss).
Research and development costs	'
	Research and development costs	The Company is actively engaged in new product development efforts for which related costs are expensed as incurred.
Fair value measurement	'
	Fair value measurement	Financial assets and liabilities are measured at fair value, which is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. The following is a fair value hierarchy based on three levels of inputs, of which the first two are considered observable and the last unobservable, that may be used to measure fair value:
		•       Level 1—Quoted prices in active markets for identical assets or liabilities.
		•       Level 2—Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities, quoted prices in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.
		•       Level 3—Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.
		The following table presents the Company’s fair value hierarchy for assets and liabilities measured at fair value on a recurring basis as of June 30, 2014 and December 31, 2013 (in thousands):
		June 30, 2014								December 31, 2013
		Level 1		Level 2		Level 3		Total		Level 1		Level 2		Level 3		Total
	Assets:
	Cash and cash equivalents	$	34,565	$	—	$	—	$	34,565	$	51,804	$	—	$	—	$	51,804
	Short-term investments:
	Corporate debt securities
	Financial		—		27,532		—		27,532		—		—		—		—
	Industrial		—		6,265		—		6,265		—		—		—		—
	Utility		—		1,451		—		1,451		—		—		—		—
	Commercial paper
	Financial		—		5,591		—		5,591		—		—		—		—
	Industrial		—		—		—		—		—		—		—		—
	Total short-term investments	$	—	$	40,839	$	—	$	40,839	$	—	$	—	$	—	$	—
	Long-term investments:
	Corporate debt securities
	Financial		—		12,778		—		12,778		—		—		—		—
	Industrial		—		6,965		—		6,965		—		—		—		—
	Utility		—		—		—		—		—		—		—		—
	Total long-term investments	$	—	$	19,743	$	—		19,743	$	—	$	—	$	—	$	—
	Total assets measured at fair value	$	34,565	$	60,582	$	—	$	95,147	$	51,804	$	—	$	—	$	51,804
	Liabilities:
	Warrant liability		—		—		182		182		—		—		129		129
	Total liabilities measured at fair value	$	—	$	—	$	182	$	182	$	—	$	—	$	129	$	129
		The Company holds available-for-sale securities that consist of highly liquid, investment grade debt securities. The Company determines the fair value of its debt securities based upon one or more valuations reported by its investment accounting and reporting service provider. The investment service provider values the securities using a hierarchical security pricing model that relies primarily on valuations provided by an industry-recognized valuation service. Such valuations may be based on trade prices in active markets for identical assets or liabilities (Level 1 inputs) or valuation models using inputs that are observable either directly or indirectly (Level 2 inputs), such as quoted prices for similar assets or liabilities, yield curves, volatility factors, credit spreads, default rates, loss severity, current market and contractual prices for the underlying instruments or debt, and broker and dealer quotes, as well as other relevant economic measures.
		The Company used Level 3 inputs for its valuation methodology for the warrant derivative liabilities. The estimated fair values were determined using a binomial option pricing model based on various
		assumptions (see Note 9). The Company’s derivative liabilities are adjusted to reflect estimated fair value at each period end, with any decrease or increase in the estimated fair value being recorded in other income or expense accordingly, as adjustments to fair value of derivative liabilities.
		The following table presents the activity for liabilities measured at estimated fair value using unobservable inputs for the six months ended June 30, 2014:
	Fair Value Measurements Using Significant Unobservable Inputs (Level 3)
		Warrant Derivative
		Liability
	Beginning Balance at December 31, 2011	$	—
	Issuances		24,500
	Ending Balance at December 31, 2012	$	24,500
	Issuances		28,300
	Adjustments to estimated fair value		76,600
	Ending Balance at December 31, 2013	$	129,400
	Adjustments to estimated fair value		52,400
	Ending Balance at June 30, 2014	$	181,800

Summary_of_Significant_Account2

Summary of Significant Accounting Policies (Tables)	6 Months Ended
	Jun. 30, 2014
Accounting Policies [Abstract]	'
Schedule of Fair Value Hierarchy for Assets and Liabilities Measured at Fair Value on Recurring Basis	'
	The following table presents the Company’s fair value hierarchy for assets and liabilities measured at fair value on a recurring basis as of June 30, 2014 and December 31, 2013 (in thousands):
		June 30, 2014								December 31, 2013
		Level 1		Level 2		Level 3		Total		Level 1		Level 2		Level 3		Total
	Assets:
	Cash and cash equivalents	$	34,565	$	—	$	—	$	34,565	$	51,804	$	—	$	—	$	51,804
	Short-term investments:
	Corporate debt securities
	Financial		—		27,532		—		27,532		—		—		—		—
	Industrial		—		6,265		—		6,265		—		—		—		—
	Utility		—		1,451		—		1,451		—		—		—		—
	Commercial paper
	Financial		—		5,591		—		5,591		—		—		—		—
	Industrial		—		—		—		—		—		—		—		—
	Total short-term investments	$	—	$	40,839	$	—	$	40,839	$	—	$	—	$	—	$	—
	Long-term investments:
	Corporate debt securities
	Financial		—		12,778		—		12,778		—		—		—		—
	Industrial		—		6,965		—		6,965		—		—		—		—
	Utility		—		—		—		—		—		—		—		—
	Total long-term investments	$	—	$	19,743	$	—		19,743	$	—	$	—	$	—	$	—
	Total assets measured at fair value	$	34,565	$	60,582	$	—	$	95,147	$	51,804	$	—	$	—	$	51,804
	Liabilities:
	Warrant liability		—		—		182		182		—		—		129		129
	Total liabilities measured at fair value	$	—	$	—	$	182	$	182	$	—	$	—	$	129	$	129
Schedule of Activity for Liabilities Measured at Estimated Fair Value Using Unobservable Inputs	'
	The following table presents the activity for liabilities measured at estimated fair value using unobservable inputs for the six months ended June 30, 2014:
	Fair Value Measurements Using Significant Unobservable Inputs (Level 3)
		Warrant Derivative
		Liability
	Beginning Balance at December 31, 2011	$	—
	Issuances		24,500
	Ending Balance at December 31, 2012	$	24,500
	Issuances		28,300
	Adjustments to estimated fair value		76,600
	Ending Balance at December 31, 2013	$	129,400
	Adjustments to estimated fair value		52,400
	Ending Balance at June 30, 2014	$	181,800

Investments_Tables

Investments (Tables)	6 Months Ended
	Jun. 30, 2014
Investments Schedule [Abstract]	'
Summary of Investments by Security Type	'
	The following table summarizes investments by security type as of June 30, 2014:
		June 30, 2014 (in thousands)
		Cost		Gross		Gross			Fair
				Unrealized		Unrealized			Market
				Gains		Losses			Value
	Available-for-sale securities:
	Corporate debt securities, short-term	$	40,840	$	—	$	(1	)	$	40,839
	Corporate debt securities, long-term	$	19,736	$	7	$	—		$	19,743
	Total	$	60,576	$	7	$	(1	)	$	60,582

Fixed_Assets_Tables

Fixed Assets (Tables)	6 Months Ended
	Jun. 30, 2014
Property Plant And Equipment [Abstract]	'
Components of Fixed Assets	'
	Fixed assets consisted of the following:
		June 30,			December 31,
		2014			2013
	Manufacturing and lab equipment	$	2,337,895		$	775,872
	Office furniture		115,461			59,095
	Computers and equipment		168,375			110,857
	Leasehold Improvements		133,067			—
			2,754,798			945,824
	Less accumulated depreciation and amortization		(225,569	)		(115,118	)
		$	2,529,229		$	830,706

Notes_Payable_Tables

Notes Payable (Tables)	6 Months Ended
	Jun. 30, 2014
Debt Disclosure [Abstract]	'
Future Minimum Principal Payments on Notes Payable	'
	Future minimum principal payments on notes payable are as follows:
	Twelve Months ending June 30,
	2015	$	1,525,442
	2016		3,212,403
	2017		3,446,423
	2018		1,815,732
	Total	$	10,000,000

StockBased_Compensation_Tables

Stock-Based Compensation (Tables)	6 Months Ended
	Jun. 30, 2014
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]	'
Summary of Stock Option Activity and Related Information	'
		A summary of the Company’s stock option activity and related information is as follows:
		Options			Weighted-			Weighted-		Aggregate
		Outstanding			Average			Average		Intrinsic
					Exercise			Remaining		Value
					Price			Contractual
								Term
	Balance at December 31, 2011		12,500		$	0.18			—	$	—
	Granted		144,159			0.39			—		—
	Exercised		—			—			—		—
	Cancelled		—			—			—		—
	Balance at December 31, 2012		156,659			0.36			—		—
	Granted		1,061,325			4.6			—		—
	Exercised		(12,290	)		0.24			—		—
	Expired		(2,154	)		0.54			—		—
	Forfeited		(70,387	)		0.45			—		—
	Balance at December 31, 2013		1,133,153		$	4.33			9.71	$	3,026,430
	Granted		1,442,000			8.02			—		—
	Exercised		(12,962	)		0.42			—		—
	Expired		(4,999	)		0.58			—		—
	Forfeited		(237,036	)		7.68			—		—
	Balance at June 30, 2014		2,320,156		$	6.31			9.56	$	6,457,975
	Exercisable at June 30, 2014		135,838		$	0.67			8.51	$	1,144,042
Assumptions Used to Estimate Fair Value of Options Granted	'
	The fair value of options granted to employees and non-employee directors was estimated at the date of grant using a Black-Scholes option pricing model with the weighted-average assumptions stated below.
		Three			Three
		Months			Months
		Ended			Ended
		June 30,			June 30,
		2014			2013
	Risk free interest rate		1.76	%		0	%
	Dividend yield		0	%		0	%
	Volatility		68.36	%		0	%
	Weighted-average expected life of option (years)		6			0
		Six			Six
		Months			Months
		Ended			Ended
		June 30,			June 30,
		2014			2013
	Risk free interest rate		1.83	%		1.18	%
	Dividend yield		0	%		0	%
	Volatility		63.83	%		59.82	%
	Weighted-average expected life of option (years)		6.02			5.99
		The fair value of options granted to non-employees was estimated at the vesting date using a Black-Scholes option pricing model with the weighted-average assumptions stated below.
		Three			Three
		Months			Months
		Ended			Ended
		June 30,			June 30,
		2014			2013
	Risk free interest rate		2.52	%		0	%
	Dividend yield		0	%		0	%
	Volatility		68.42	%		0	%
	Weighted-average expected life of option (years)		9.95			0
		The fair value of options granted to non-employees was estimated at the vesting date using a Black-Scholes option pricing model with the weighted-average assumptions stated below.
		Six			Six
		Months			Months
		Ended			Ended
		June 30,			June 30,
		2014			2013
	Risk free interest rate		2.5	%		2.05	%
	Dividend yield		0	%		0	%
	Volatility		68.37	%		59.25	%
	Weighted-average expected life of option (years)		9.85			10

Warrants_Tables

Warrants (Tables)	6 Months Ended
	Jun. 30, 2014
Derivative Instruments And Hedging Activities Disclosure [Abstract]	'
Valuation of Derivative Liabilities Using a Binomial Pricing Model with Weighted Average Assumptions	'
	The derivative liabilities were valued at their issuance dates and at the end of each reporting period using a binomial pricing model and the following weighted average assumptions:
		June 30, 2014			June 30, 2013
	Expected volatility		69.5	%		39.6	%
	Risk-free interest rate		1.77	%		1.69	%
	Dividend yield		0	%		0	%
	Remaining expected term of underlying securities (years)		5.57			6.67

Commitments_and_Contingencies_

Commitments and Contingencies (Tables)	6 Months Ended
	Jun. 30, 2014
Commitments And Contingencies Disclosure [Abstract]	'
Future Minimum Lease Payments Under Operating Leases	'
	Future minimum lease payments required under the operating leases are as follows:
	Twelve Months Ending June,
	2015	$	475,500
	2016		788,300
	2017		758,600
	2018		781,300
	2019		804,700
	Thereafter		274,900
	Total	$	3,883,300

Summary_of_Significant_Account3

Summary of Significant Accounting Policies - Additional Information (Detail) (USD $)	6 Months Ended		34 Months Ended
	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Dec. 31, 2013
Accounting Policies [Line Items]	'	'	'	'
Retained Earnings (Accumulated Deficit)	$25,102,254	'	$25,102,254	$15,572,940
Net cash used in operating activities	-6,251,501	-2,055,991	-20,379,808	'
Other-than-temporary impairment charges	'	'	$0	'
Minimum [Member]	'	'	'	'
Accounting Policies [Line Items]	'	'	'	'
Property, plant and equipment, useful life	'3 years	'	'	'
Maximum [Member]	'	'	'	'
Accounting Policies [Line Items]	'	'	'	'
Property, plant and equipment, useful life	'7 years	'	'	'

Summary_of_Significant_Account4

Summary of Significant Accounting Policies - Schedule of Fair Value Hierarchy for Assets and Liabilities Measured at Fair Value on Recurring Basis (Detail) (USD $)	Jun. 30, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Assets:	'	'
Cash and cash equivalents	$34,565	$51,804
Total assets measured at fair value	95,147	51,804
Liabilities:	'	'
Warrant liability	182	129
Total liabilities measured at fair value	182	129
Short-Term Investments [Member]	'	'
Assets:	'	'
Investments	40,839	0
Short-Term Investments [Member] | Corporate Debt Securities [Member] | Financial [Member]	'	'
Assets:	'	'
Investments	27,532	0
Short-Term Investments [Member] | Corporate Debt Securities [Member] | Industrial [Member]	'	'
Assets:	'	'
Investments	6,265	0
Short-Term Investments [Member] | Corporate Debt Securities [Member] | Utility [Member]	'	'
Assets:	'	'
Investments	1,451	0
Short-Term Investments [Member] | Commercial Paper [Member] | Financial [Member]	'	'
Assets:	'	'
Investments	5,591	0
Short-Term Investments [Member] | Commercial Paper [Member] | Industrial [Member]	'	'
Assets:	'	'
Investments	0	0
Long-Term Investments [Member]	'	'
Assets:	'	'
Investments	19,743	0
Long-Term Investments [Member] | Corporate Debt Securities [Member] | Financial [Member]	'	'
Assets:	'	'
Investments	12,778	0
Long-Term Investments [Member] | Corporate Debt Securities [Member] | Industrial [Member]	'	'
Assets:	'	'
Investments	6,965	0
Long-Term Investments [Member] | Corporate Debt Securities [Member] | Utility [Member]	'	'
Assets:	'	'
Investments	'	0
Level 1 [Member]	'	'
Assets:	'	'
Cash and cash equivalents	34,565	51,804
Total assets measured at fair value	34,565	51,804
Liabilities:	'	'
Warrant liability	0	0
Total liabilities measured at fair value	0	0
Level 1 [Member] | Short-Term Investments [Member]	'	'
Assets:	'	'
Investments	0	0
Level 1 [Member] | Short-Term Investments [Member] | Corporate Debt Securities [Member] | Financial [Member]	'	'
Assets:	'	'
Investments	0	0
Level 1 [Member] | Short-Term Investments [Member] | Corporate Debt Securities [Member] | Industrial [Member]	'	'
Assets:	'	'
Investments	0	0
Level 1 [Member] | Short-Term Investments [Member] | Corporate Debt Securities [Member] | Utility [Member]	'	'
Assets:	'	'
Investments	0	0
Level 1 [Member] | Short-Term Investments [Member] | Commercial Paper [Member] | Financial [Member]	'	'
Assets:	'	'
Investments	0	0
Level 1 [Member] | Short-Term Investments [Member] | Commercial Paper [Member] | Industrial [Member]	'	'
Assets:	'	'
Investments	0	0
Level 1 [Member] | Long-Term Investments [Member]	'	'
Assets:	'	'
Investments	0	0
Level 1 [Member] | Long-Term Investments [Member] | Corporate Debt Securities [Member] | Financial [Member]	'	'
Assets:	'	'
Investments	0	0
Level 1 [Member] | Long-Term Investments [Member] | Corporate Debt Securities [Member] | Industrial [Member]	'	'
Assets:	'	'
Investments	0	0
Level 1 [Member] | Long-Term Investments [Member] | Corporate Debt Securities [Member] | Utility [Member]	'	'
Assets:	'	'
Investments	0	0
Level 2 [Member]	'	'
Assets:	'	'
Total assets measured at fair value	60,582	0
Liabilities:	'	'
Warrant liability	0	0
Total liabilities measured at fair value	0	0
Level 2 [Member] | Short-Term Investments [Member]	'	'
Assets:	'	'
Investments	40,839	0
Level 2 [Member] | Short-Term Investments [Member] | Corporate Debt Securities [Member] | Financial [Member]	'	'
Assets:	'	'
Investments	27,532	0
Level 2 [Member] | Short-Term Investments [Member] | Corporate Debt Securities [Member] | Industrial [Member]	'	'
Assets:	'	'
Investments	6,265	0
Level 2 [Member] | Short-Term Investments [Member] | Corporate Debt Securities [Member] | Utility [Member]	'	'
Assets:	'	'
Investments	1,451	0
Level 2 [Member] | Short-Term Investments [Member] | Commercial Paper [Member] | Financial [Member]	'	'
Assets:	'	'
Investments	5,591	0
Level 2 [Member] | Short-Term Investments [Member] | Commercial Paper [Member] | Industrial [Member]	'	'
Assets:	'	'
Investments	'	0
Level 2 [Member] | Long-Term Investments [Member]	'	'
Assets:	'	'
Investments	19,743	0
Level 2 [Member] | Long-Term Investments [Member] | Corporate Debt Securities [Member] | Financial [Member]	'	'
Assets:	'	'
Investments	12,778	0
Level 2 [Member] | Long-Term Investments [Member] | Corporate Debt Securities [Member] | Industrial [Member]	'	'
Assets:	'	'
Investments	6,965	0
Level 2 [Member] | Long-Term Investments [Member] | Corporate Debt Securities [Member] | Utility [Member]	'	'
Assets:	'	'
Investments	'	0
Level 3 [Member]	'	'
Assets:	'	'
Total assets measured at fair value	0	0
Liabilities:	'	'
Warrant liability	182	129
Total liabilities measured at fair value	182	129
Level 3 [Member] | Short-Term Investments [Member]	'	'
Assets:	'	'
Investments	0	0
Level 3 [Member] | Short-Term Investments [Member] | Corporate Debt Securities [Member] | Financial [Member]	'	'
Assets:	'	'
Investments	0	0
Level 3 [Member] | Short-Term Investments [Member] | Corporate Debt Securities [Member] | Industrial [Member]	'	'
Assets:	'	'
Investments	0	0
Level 3 [Member] | Short-Term Investments [Member] | Corporate Debt Securities [Member] | Utility [Member]	'	'
Assets:	'	'
Investments	0	0
Level 3 [Member] | Short-Term Investments [Member] | Commercial Paper [Member] | Financial [Member]	'	'
Assets:	'	'
Investments	0	0
Level 3 [Member] | Short-Term Investments [Member] | Commercial Paper [Member] | Industrial [Member]	'	'
Assets:	'	'
Investments	0	0
Level 3 [Member] | Long-Term Investments [Member]	'	'
Assets:	'	'
Investments	0	0
Level 3 [Member] | Long-Term Investments [Member] | Corporate Debt Securities [Member] | Financial [Member]	'	'
Assets:	'	'
Investments	0	0
Level 3 [Member] | Long-Term Investments [Member] | Corporate Debt Securities [Member] | Industrial [Member]	'	'
Assets:	'	'
Investments	0	0
Level 3 [Member] | Long-Term Investments [Member] | Corporate Debt Securities [Member] | Utility [Member]	'	'
Assets:	'	'
Investments	$0	$0

Summary_of_Significant_Account5

Summary of Significant Accounting Policies - Schedule of Activity for Liabilities Measured at Estimated Fair Value Using Unobservable Inputs (Detail) (USD $)	6 Months Ended	12 Months Ended
	Jun. 30, 2014	Dec. 31, 2013	Dec. 31, 2012
Fair Value Disclosures [Abstract]	'	'	'
Beginning Balance	$129,400	$24,500	'
Issuances	'	28,300	24,500
Adjustments to estimated fair value	52,400	76,600	'
Ending Balance	$181,800	$129,400	$24,500

Reverse_Merger_Additional_Info

Reverse Merger - Additional Information (Detail)	1 Months Ended	6 Months Ended
	Oct. 31, 2013	Jun. 30, 2014	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Business Acquisition [Line Items]	'	'	'	'	'
Merger closure date	'	31-Oct-13	'	'	'
Conversion basis of preferred stock to common stock	'	'One-to-one	'	'	'
Reverse stock split conversion ratio	0.01	'	'	'	'
Common Stock, shares outstanding	'	19,579,588	13,934,876	'	'
Share based compensation, Outstanding option	'	2,320,156	1,133,153	156,659	12,500
Series A Convertible Preferred Stock [Member]	'	'	'	'	'
Business Acquisition [Line Items]	'	'	'	'	'
Reverse stock split conversion ratio	0.3333	'	'	'	'
Merger Transactions [Member]	'	'	'	'	'
Business Acquisition [Line Items]	'	'	'	'	'
Conversion basis of preferred stock to common stock	'	'One-to-one	'	'	'
Preferred stock conversion ratio	1	'	'	'	'
Common Stock, shares outstanding	4,916,469	'	'	'	'
Ownership percentage by former stockholders of Ignyta	99.85%	'	'	'	'
Shares reserved for issuance pursuant to future equity grants	342,209	'	'	'	'
Merger Transactions [Member] | Common Stock [Member] | Maximum [Member]	'	'	'	'	'
Business Acquisition [Line Items]	'	'	'	'	'
Number of securities called by warrants	25,001	'	'	'	'
Merger Transactions [Member] | 2011 Equity Incentive Plan [Member]	'	'	'	'	'
Business Acquisition [Line Items]	'	'	'	'	'
Share based compensation, Outstanding option	358,986	'	'	'	'
Merger Transactions [Member] | Series A Convertible Preferred Stock [Member]	'	'	'	'	'
Business Acquisition [Line Items]	'	'	'	'	'
Reverse stock split conversion ratio	0.3333	'	'	'	'
Reverse stock split ratio	'	'Three-to-one	'	'	'
Merger Transactions [Member] | Common Stock [Member]	'	'	'	'	'
Business Acquisition [Line Items]	'	'	'	'	'
Warrants to purchase stock, outstanding	25,001	'	'	'	'

Actagene_Merger_Additional_Inf

Actagene Merger - Additional Information (Detail)	0 Months Ended	6 Months Ended
	20-May-13	Jun. 30, 2014
Business Acquisition [Line Items]	'	'
Merger closure date	'	31-Oct-13
Actagene Merger [Member]	'	'
Business Acquisition [Line Items]	'	'
Common stock in exchange for the cancellation of all of the outstanding shares of Actagene	1,583,336	'
Merger closure date	'	20-May-13
Percentage of voting power in each entity	60.00%	'

Investments_Summary_of_Investm

Investments - Summary of Investments by Security Type (Detail) (USD $)	6 Months Ended
In Thousands, unless otherwise specified	Jun. 30, 2014
Schedule of Available-for-sale Securities [Line Items]	'
Available-for-sale securities, Cost	$60,576
Available-for-sale securities, Gross Unrealized Gains	7
Available-for-sale securities, Gross Unrealized Losses	-1
Available-for-sale securities, Fair Market Value	60,582
Corporate Debt Securities Short Term [Member]	'
Schedule of Available-for-sale Securities [Line Items]	'
Available-for-sale securities, Cost	40,840
Available-for-sale securities, Gross Unrealized Gains	0
Available-for-sale securities, Gross Unrealized Losses	-1
Available-for-sale securities, Fair Market Value	40,839
Corporate Debt Securities Long Term [Member]	'
Schedule of Available-for-sale Securities [Line Items]	'
Available-for-sale securities, Cost	19,736
Available-for-sale securities, Gross Unrealized Gains	7
Available-for-sale securities, Gross Unrealized Losses	0
Available-for-sale securities, Fair Market Value	$19,743

Fixed_Assets_Components_of_Fix

Fixed Assets - Components of Fixed Assets (Detail) (USD $)	Jun. 30, 2014	Dec. 31, 2013
Property Plant And Equipment [Abstract]	'	'
Manufacturing and lab equipment	$2,337,895	$775,872
Office furniture	115,461	59,095
Computers and equipment	168,375	110,857
Leasehold Improvements	133,067	'
Fixed Assets - Gross	2,754,798	945,824
Less accumulated depreciation and amortization	-225,569	-115,118
Fixed Assets - Net	$2,529,229	$830,706

Fixed_Assets_Additional_Inform

Fixed Assets - Additional Information (Detail) (USD $)	3 Months Ended		6 Months Ended		34 Months Ended
	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014
Property Plant And Equipment Useful Life And Values [Abstract]	'	'	'	'	'
Depreciation expense	$63,108	$27,514	$111,708	$48,076	$237,980

Notes_Payable_Additional_Infor

Notes Payable - Additional Information (Detail) (USD $)

3 Months Ended

6 Months Ended

12 Months Ended

34 Months Ended

Jun. 30, 2014

Jun. 30, 2013

Jun. 30, 2014

Jun. 30, 2013

Dec. 31, 2013

Dec. 31, 2012

Jun. 30, 2014

Feb. 27, 2013

Jul. 31, 2013

Feb. 27, 2013

Dec. 31, 2012

Jun. 30, 2012

Series B Convertible Preferred Stock [Member]

Series B Convertible Preferred Stock [Member]

Series B Convertible Preferred Stock [Member]

Series B Convertible Preferred Stock [Member]

Debt Instrument [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

Loan, maximum borrowing amount

'

'

'

'

$10,000,000

'

'

$1,500,000

'

'

'

'

Final payment of borrowing, presented as debt discount

'

'

'

'

1,050,000

'

'

'

'

'

'

'

Percentage of principal amount of new loan to be paid as final payment

'

'

'

'

10.50%

'

'

'

'

'

'

'

Principal and interest payment period commencing after period of interest only payments

'

'

'

'

'36 months

'

'

'

'

'

'

'

Interest only payments period

'

'

'

'

'12 months

'

'

'

'

'

'

'

Fixed interest on the advanced amount

'

'

'

'

6.92%

'

'

'

'

'

'

'

New loan agreement maturity date

'

'

'

'

1-Dec-17

'

'

'

'

'

'

'

Warrant to purchase stock, shares

'

'

'

'

'

'

'

'

16,667

16,667

8,334

8,334

Percentage of loan agreement up to a number of stock on which warrant to purchase common stock issued

'

'

'

'

'

'

'

'

'

5.00%

'

'

Warrants issued with debt financing recorded as debt discount

'

'

'

12,100

28,300

24,500

52,800

'

'

'

'

'

Interest expense due to amortization of the debt discount

$73,102

$3,367

$147,463

$5,494

'

'

$200,263

'

'

'

'

'

Notes_Payable_Future_Minimum_P

Notes Payable - Future Minimum Principal Payments on Notes Payable (Detail) (USD $)	Jun. 30, 2014
Debt Disclosure [Abstract]	'
2015	$1,525,442
2016	3,212,403
2017	3,446,423
2018	1,815,732
Total	$10,000,000

Stockholders_Equity_Additional

Stockholders' Equity - Additional Information (Detail) (USD $)

1 Months Ended

6 Months Ended

34 Months Ended

0 Months Ended

1 Months Ended

12 Months Ended

0 Months Ended

Oct. 31, 2013

Jun. 30, 2014

Jun. 30, 2014

Dec. 31, 2013

Oct. 30, 2013

Mar. 19, 2014

Oct. 31, 2013

Dec. 31, 2012

Dec. 31, 2011

Dec. 31, 2012

Nov. 29, 2013

Nov. 06, 2013

Nov. 29, 2013

Nov. 06, 2013

Nov. 06, 2013

Common Stock [Member]

Series A Convertible Preferred Stock [Member]

Series A Convertible Preferred Stock [Member]

Series A Convertible Preferred Stock [Member]

Series B Convertible Preferred Stock [Member]

Private Investment in Public Equity ( the "PIPE" Financing") [Member]

Private Investment in Public Equity ( the "PIPE" Financing") [Member]

Private Investment in Public Equity ( the "PIPE" Financing") [Member]

Private Investment in Public Equity ( the "PIPE" Financing") [Member]

Private Investment in Public Equity ( the "PIPE" Financing") [Member]

Investor

Investor

Common Stock [Member]

Common Stock [Member]

Common Stock [Member]

Class of Stock [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Common Stock, shares authorized

'

150,000,000

150,000,000

150,000,000

'

'

'

'

'

'

'

'

'

'

'

Preferred Stock, shares authorized

'

10,000,000

10,000,000

10,000,000

'

'

'

'

'

'

'

'

'

'

'

Common Stock, voting right description

'

'Common stock is entitled to one vote, and all shares rank equally as to voting and other matters.

'

'

'

'

'

'

'

'

'

'

'

'

'

Stock issued

'

'

'

'

'

6,031,750

'

416,667

416,667

1,835,000

'

'

1,270,096

7,740,142

'

Sales of common stock, price per share

'

'

'

'

'

$9.15

'

'

'

'

'

'

$6

'

$6

Gross proceeds from sale of stock

'

'

'

'

'

$55,200,000

'

'

'

'

'

'

$7,600,000

$46,400,000

'

Number of accredited investors

'

'

'

'

'

'

'

'

'

'

195

52

'

'

'

Reverse stock split ratio

0.01

'

'

'

'

'

0.3333

'

'

'

'

'

'

'

'

Common Stock, par value

$0.00

$0.00

$0.00

$0.00

$0.00

'

'

'

'

'

'

'

'

'

'

Issuance of Preferred Stock, price per share

'

'

'

'

'

'

'

$0.60

$0.60

$3

'

'

'

'

'

Proceeds from issuance of preferred stock

'

'

$5,893,951

'

'

'

'

$250,000

$250,000

$5,505,000

'

'

'

'

'

Conversion basis of preferred stock to common stock

'

'One-to-one

'

'

'

'

'

'

'

'

'

'

'

'

'

StockBased_Compensation_Additi

Stock-Based Compensation - Additional Information (Detail) (USD $)

3 Months Ended

6 Months Ended

12 Months Ended

34 Months Ended

0 Months Ended

1 Months Ended

3 Months Ended

6 Months Ended

34 Months Ended

3 Months Ended

6 Months Ended

34 Months Ended

3 Months Ended

6 Months Ended

34 Months Ended

3 Months Ended

6 Months Ended

0 Months Ended

3 Months Ended

6 Months Ended

6 Months Ended

12 Months Ended

Jun. 30, 2014

Jun. 30, 2013

Jun. 30, 2014

Jun. 30, 2013

Dec. 31, 2012

Dec. 31, 2011

Jun. 30, 2014

Feb. 28, 2014

Dec. 31, 2013

Oct. 31, 2013

Feb. 28, 2013

20-May-13

Feb. 28, 2014

Jun. 30, 2014

Jun. 30, 2013

Jun. 30, 2014

Jun. 30, 2013

Jun. 30, 2014

Jun. 30, 2014

Jun. 30, 2013

Jun. 30, 2014

Jun. 30, 2013

Jun. 30, 2014

Jun. 30, 2014

Jun. 30, 2013

Jun. 30, 2014

Jun. 30, 2013

Jun. 30, 2014

Jun. 30, 2014

Jun. 30, 2013

Jun. 30, 2014

Jun. 30, 2013

Jun. 11, 2014

Jun. 11, 2014

Jun. 30, 2014

Jun. 30, 2013

Jun. 30, 2014

Jun. 30, 2013

Jun. 30, 2014

Jun. 30, 2014

Jun. 30, 2014

Jun. 30, 2014

Jun. 30, 2014

Jun. 30, 2014

Jun. 30, 2014

Jun. 30, 2014

Dec. 31, 2011

Actagene Merger [Member]

Actagene Merger [Member]

Actagene Merger [Member]

Actagene Merger [Member]

Actagene Merger [Member]

Actagene Merger [Member]

Actagene Merger [Member]

Research and Development Expense [Member]

Research and Development Expense [Member]

Research and Development Expense [Member]

Research and Development Expense [Member]

Research and Development Expense [Member]

General and Administrative Expense [Member]

General and Administrative Expense [Member]

General and Administrative Expense [Member]

General and Administrative Expense [Member]

General and Administrative Expense [Member]

Non-Employee Stock Options [Member]

Non-Employee Stock Options [Member]

Non-Employee Stock Options [Member]

Non-Employee Stock Options [Member]

Employee and Non-employee Stock Options [Member]

Employee and Non-employee Stock Options [Member]

Stock Options [Member]

Stock Options [Member]

Stock Options [Member]

Stock Options [Member]

Stock Options [Member]

Stock Options [Member]

Stock Options [Member]

Stock Options [Member]

Stock Options [Member]

Stock Options [Member]

Stock Options [Member]

Restricted Stock [Member]

Restricted Stock [Member]

2014 Plan [Member]

2011 Plan [Member]

Maximum [Member]

Minimum [Member]

2014 Plan [Member]

2011 Plan [Member]

Inducement Stock Plan [Member]

Stock Option One [Member]

Stock Option One [Member]

Minimum [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Issuance of equity awards

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

3,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Number of shares issued for each share subject to a stock option outstanding

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

1

'

'

'

'

'

'

1

'

'

'

'

'

'

Initial share reserve

'

'

'

'

'

'

'

1,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Common stock available for issuance

'

'

'

'

'

166,666

'

'

2,712,652

712,652

666,666

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Common stock reserved for issuance

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

3,000,000

2,712,652

1,000,000

'

'

'

'

Shares that remained available for grant

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

2,910,000

1,607,071

190,000

'

'

'

'

Number of additional equity grants

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0

'

'

'

'

Options expiration period from their date of grant

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'10 years

'

'

'

'

'

'

'

'

Total combined voting power

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

10.00%

'

'

'

'

'

'

'

Exercise price of option as a percentage of fair market value of common Stock on the grant date

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

100.00%

'

'

'

'

110.00%

'

'

Stock options granted, term

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'5 years

'

'

'

Estimated weighted-average fair value of stock options granted

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$6.94

$0

$6.65

$0.42

'

'

$4.51

$0

$4.70

$0.33

'

'

'

'

'

'

'

'

'

Options granted during period, maximum contractual term

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'9 years 11 months 12 days

'0 years

'9 years 10 months 6 days

'10 years

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Stock-based compensation expense for employees and non-employees

$346,040

$16,602

$661,146

$38,986

'

'

$1,025,759

'

'

'

'

'

'

'

'

'

'

'

$99,791

$9,884

$153,259

$29,304

$380,992

$246,249

$6,719

$507,887

$9,682

$644,767

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Unrecognized compensation cost related to unvested stock-based awards

8,000,700

'

8,000,700

'

'

'

8,000,700

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Unrecognized compensation cost related to unvested stock-based awards, weighted average period of recognition

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'3 years 6 months 26 days

'

'

'

'

'

'

'

'

'

'

Common Stock in exchange for the cancellation of all of the outstanding shares of Actagene

'

'

'

'

'

666,668

'

'

'

'

'

1,583,336

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Proceed from sale of shares of restricted stock

'

'

51,581,843

'

'

2,000

102,595,584

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Shares of restricted stock, vested

'

'

'

'

'

'

'

'

'

'

'

1,000,000

'

'

'

1,133,952

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

635,334

600,000

Shares of restricted stock, unvested

'

'

'

'

'

'

'

'

'

'

'

'

183,336

49,384

'

49,384

'

49,384

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

18,000

66,668

Shares of common stock repurchased

'

'

'

'

13,334

'

'

'

'

'

'

'

400,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Stock-based compensation, restricted stock

$18,180

$2,040

$34,780

$3,240

'

'

$64,760

'

'

'

'

'

'

$16,831

$0

$121,404

$0

$121,404

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Shares vesting period

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'4 years

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

StockBased_Compensation_Summar

Stock-Based Compensation - Summary of Stock Option Activity and Related Information (Detail) (USD $)	6 Months Ended	12 Months Ended
	Jun. 30, 2014	Dec. 31, 2013	Dec. 31, 2012
Options Outstanding	'	'	'
Balance at beginning of period	1,133,153	156,659	12,500
Granted	1,442,000	1,061,325	144,159
Exercised	-12,962	-12,290	'
Cancelled	'	'	'
Expired	-4,999	-2,154	'
Forfeited	-237,036	-70,387	'
Balance at end of period	2,320,156	1,133,153	156,659
Exercisable at end of period	135,838	'	'
Weighted-Average Exercise Price	'	'	'
Balance at beginning of period	$4.33	$0.36	$0.18
Granted	$8.02	$4.60	$0.39
Exercised	$0.42	$0.24	'
Cancelled	'	'	'
Expired	$0.58	$0.54	'
Forfeited	$7.68	$0.45	'
Balance at end of period	$6.31	$4.33	$0.36
Exercisable at end of period	$0.67	'	'
Weighted- Average Remaining Contractual Term	'	'	'
Balance at end of period	'9 years 6 months 22 days	'9 years 8 months 16 days	'
Exercisable at end of period	'8 years 6 months 4 days	'	'
Aggregate Intrinsic Value	'	'	'
Balance at end of period	$6,457,975	$3,026,430	'
Exercisable at end of period	$1,144,042	'	'

StockBased_Compensation_Assump

Stock-Based Compensation - Assumptions Used to Estimate Fair Value of Options Granted (Detail)	3 Months Ended		6 Months Ended
	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2013
Employee and Non-employee Directors Stock Options [Member]	'	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'	'
Risk free interest rate	1.76%	0.00%	1.83%	1.18%
Dividend yield	0.00%	0.00%	0.00%	0.00%
Volatility	68.36%	0.00%	63.83%	59.82%
Weighted-average expected life of option (years)	'6 years	'0 years	'6 years 7 days	'5 years 11 months 27 days
Non-Employee Stock Options [Member]	'	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'	'
Risk free interest rate	2.52%	0.00%	2.50%	2.05%
Dividend yield	0.00%	0.00%	0.00%	0.00%
Volatility	68.42%	0.00%	68.37%	59.25%
Weighted-average expected life of option (years)	'9 years 11 months 12 days	'0 years	'9 years 10 months 6 days	'10 years

Warrants_Additional_Informatio

Warrants - Additional Information (Detail) (USD $)	6 Months Ended		34 Months Ended	0 Months Ended				0 Months Ended	6 Months Ended
	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Feb. 27, 2013	Jul. 31, 2013	Dec. 31, 2012	Jun. 30, 2012	Nov. 06, 2013	Jun. 30, 2014	Nov. 06, 2013
				Series B Convertible Preferred Stock [Member]	Series B Convertible Preferred Stock [Member]	Series B Convertible Preferred Stock [Member]	Series B Convertible Preferred Stock [Member]	Licensing Agreements [Member]	Licensing Agreements [Member]	Licensing Agreements [Member]
								Common Stock [Member]	Common Stock [Member]	Common Stock [Member]
Class of Warrant or Right [Line Items]	'	'	'	'	'	'	'	'	'	'
Warrant to purchase stock, shares	'	'	'	16,667	16,667	8,334	8,334	'	'	16,667
Warrant exercise price per share	'	'	'	$3	'	$3	'	'	'	$6
Warrant exercise period	'	'	'	'	'	'	'	6-Nov-18	'	'
Warrant expense	'	'	$47,600	'	'	'	'	'	$47,600	'
Exercise price	'	'	'	'	'	'	'	'	$6	'
Risk-free interest rate	1.77%	1.69%	'	'	'	'	'	'	1.68%	'
Expected volatility	69.50%	39.60%	'	'	'	'	'	'	54.80%	'
Useful life	'5 years 6 months 26 days	'6 years 8 months 1 day	'	'	'	'	'	'	'4 years 10 months 6 days	'
Percentage of loan agreement up to a number of stock on which warrant to purchase common stock issued	'	'	'	5.00%	'	'	'	'	'	'
Warrant expiry date	'	'	'	27-Feb-20	'	'	'	'	'	'
Estimated fair value of outstanding warrant liability	181,800	30,900	181,800	'	'	'	'	'	'	'
(Expense) income due to change in the estimated fair value of the derivative liability	$52,400	($5,700)	$129,000	'	'	'	'	'	'	'

Warrants_Valuation_of_Derivati

Warrants - Valuation of Derivative Liabilities Using a Binomial Pricing Model with Weighted Average Assumptions (Detail)	6 Months Ended
	Jun. 30, 2014	Jun. 30, 2013
Fair Value Disclosures [Abstract]	'	'
Expected volatility	69.50%	39.60%
Risk-free interest rate	1.77%	1.69%
Dividend yield	0.00%	0.00%
Remaining expected term of underlying securities (years)	'5 years 6 months 26 days	'6 years 8 months 1 day

Income_Taxes_Additional_Inform

Income Taxes - Additional Information (Detail) (USD $)	Jun. 30, 2014
Income Tax Disclosure [Abstract]	'
Valuation allowance	$0

Commitments_and_Contingencies_1

Commitments and Contingencies - Additional Information (Detail) (USD $)

1 Months Ended

6 Months Ended

0 Months Ended

0 Months Ended

3 Months Ended

6 Months Ended

34 Months Ended

3 Months Ended

6 Months Ended

34 Months Ended

Mar. 31, 2012

Jun. 30, 2014

Mar. 31, 2014

Nov. 06, 2013

Nov. 06, 2013

Nov. 06, 2013

Nov. 06, 2013

Nov. 06, 2013

Jun. 30, 2014

Jun. 30, 2013

Jun. 30, 2014

Jun. 30, 2013

Jun. 30, 2014

Jun. 30, 2014

Jun. 30, 2013

Jun. 30, 2014

Jun. 30, 2013

Jun. 30, 2014

Licensing Agreements [Member]

Licensing Agreements [Member]

Licensing Agreements [Member]

Licensing Agreements [Member]

Licensing Agreements [Member]

Office Building [Member]

Office Building [Member]

Office Building [Member]

Office Building [Member]

Office Building [Member]

Equipment [Member]

Equipment [Member]

Equipment [Member]

Equipment [Member]

Equipment [Member]

Maximum [Member]

Minimum [Member]

Common Stock [Member]

Common Stock [Member]

Loss Contingencies [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Operating leases, rent expense

'

'

'

'

'

'

'

'

$111,204

$41,081

$158,680

$59,382

$335,551

$22,126

$16,368

$44,252

$16,368

$104,872

Operating leases, expiration dates

'

'

'

'

'

'

'

'

'

'

'Operating leases expiring on various dates through October 2019.

'

'

'

'

'Operating lease that expires in March 2016.

'

'

Operating leases, monthly rental payment

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

5,758

'

'

Annual license payments

15,000

'

'

7,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Warrant to purchase stock, term

'

'

'

'

'

'

'5 years

'

'

'

'

'

'

'

'

'

'

'

Warrant to purchase stock, shares

'

'

'

'

'

'

'

16,667

'

'

'

'

'

'

'

'

'

'

Warrant to purchase stock, exercise price per share

'

'

'

'

'

'

'

$6

'

'

'

'

'

'

'

'

'

'

Contingent milestone payments

'

'

'

'

105,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

Amount of service to be performed by NMS under the agreement

'

'

'

'

'

1,000,000

'

'

'

'

'

'

'

'

'

'

'

'

Additional clinical expenses

'

'

$10,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Estimated cost period

'

'Over a two-year period

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Commitments_and_Contingencies_2

Commitments and Contingencies - Future Minimum Lease Payments Under Operating Leases (Detail) (USD $)	Jun. 30, 2014
Leases [Abstract]	'
2015	$475,500
2016	788,300
2017	758,600
2018	781,300
2019	804,700
Thereafter	274,900
Total	$3,883,300

Related_Parties_Additional_Inf

Related Parties - Additional Information (Detail) (Majority Stockholder [Member], USD $)	3 Months Ended		6 Months Ended		34 Months Ended
	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014
Majority Stockholder [Member]	'	'	'	'	'
Related Party Transaction [Line Items]	'	'	'	'	'
Total reimbursements received	$0	$95	$0	$5,372	$19,397
Accounts receivable	0	0	0	0	0
Total payments	$453	$19,241	$1,165	$22,409	$40,215

401k_Plan_Additional_Informati

401(k) Plan - Additional Information (Detail)	6 Months Ended
	Jun. 30, 2014
Schedule Of Sale Of Subsidiary [Abstract]	'
Eligible days of service	'21 years
Employer matching contribution percentage	0.00%
Employees contribution percentage	100.00%

Subsequent_Events_Additional_I

Subsequent Events - Additional Information (Detail) (USD $)	1 Months Ended	0 Months Ended
	Mar. 31, 2012	Aug. 04, 2014	Aug. 04, 2014
		Subsequent Event [Member]	Maximum [Member]
			Subsequent Event [Member]
Subsequent Event [Line Items]	'	'	'
Annual license payments	$15,000	$3,500,000	'
Contingent milestone payments	'	'	$102,000,000